Featuring

- **NCCN Reimbursement Resource Room**
  Visit and learn about reimbursement help and services available.

- **Health Information Technology Row**
  Visit and learn how HIT tools use NCCN Content to assist oncology practices.

- **NCCN Patient Advocacy Pavilion**
  Visit patient advocacy kiosks representing a range of disease types.

- **Exhibitor Showcase Presentations**
  Hear about new products and programs in oncology.

- **NCCN Trends™ Survey Kiosks & Exhibitor Passport**
  Complete the NCCN Trends™ Surveys or an Exhibitor Passport to receive a free gift, while supplies last.

- **General Poster Sessions**
  “Follow the Experts” Guided Poster Tours. See more information starting on page 30.

**Exhibition Hall**

**Sebastian J & I**

**Friday, March 20**

7:00 AM – 3:55 PM

5:30 – 7:30 PM (Welcome Reception)

**Saturday, March 21**

7:00 AM – 3:45 PM

**Complimentary Wi-Fi for Your Convenience**

SSID: NCCN2020Conference
Password: AC20NCCN

Sponsored by: Eisai Inc.; GSK; Incyte Corporation; Janssen Oncology; Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.; Regeneron Pharmaceuticals; AstraZeneca; Galera Therapeutics; Jazz Pharmaceuticals, Inc.; Sanofi Genzyme; Servier; and Teva Oncology.

**DOWNLOAD:**
CrowdCompass AttendeeHub

**SEARCH:**
NCCN 2020 Annual Conference

**PASSWORD:**
AC20NCCN
Siltuximab (SYLVANT®) is now recommended by the National Comprehensive Cancer Network® (NCCN®) as a preferred treatment option for idiopathic multicentric Castleman disease (iMCD) for plasmacytic/mixed histology.1

Siltuximab continues to be the first-line therapy recommended by the Castleman Disease Collaborative Network (CDCN) guidelines with Category 1 evidence, regardless of histopathologic subtype.2

The only FDA-approved therapy for the treatment of patients with multicentric Castleman disease (MCD) who are negative for human immunodeficiency virus (HIV) and human herpesvirus 8 (HHV-8).3

Limitations of use: SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.3

Please see us at booth #507 to learn more.


©2020 EUSA Pharma. All rights reserved.
Important Safety Information

Indications and Usage
SYLVANT® (siltuximab) is indicated for the treatment of patients with multicentric Castleman’s disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative.

Limitations of Use
SYLVANT was not studied in patients with MCD who are HIV positive or HHV-8 positive because SYLVANT did not bind to virally produced IL-6 in a nonclinical study.

Contraindications
Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT.

Warnings and Precautions

Concurrent Active Severe Infections
Do not administer SYLVANT to patients with severe infections until the infection resolves. SYLVANT may mask signs and symptoms of acute inflammation including suppression of fever and of acute Phase reactants such as C-reactive protein (CRP). Monitor patients receiving SYLVANT closely for infections. Institute prompt anti-infective therapy and do not administer further SYLVANT until the infection resolves.

Vaccinations
Do not administer live vaccines to patients receiving SYLVANT because IL-6 inhibition may interfere with the normal immune response to new antigens.

Infusion Related Reaction and Hypersensitivity
If treatment criteria outlined in Table 1 of the Dosage & Administration section of the Prescribing Information are not met, consider delaying treatment with SYLVANT. Do not reduce dose.

Stop the infusion of SYLVANT if the patient develops signs of anaphylaxis. Discontinue further therapy with SYLVANT.

Stop the infusion if the patient develops a mild to moderate infusion reaction. If the reaction resolves, the SYLVANT infusion may be restarted at a lower infusion rate. Consider medicating with antihistamines, acetaminophen, and corticosteroids.

Discontinue SYLVANT if the patient does not tolerate the infusion following these interventions.

Gastrointestinal (GI) Perforation
Gastrointestinal (GI) perforation has been reported in clinical trials although not in MCD trials. Use with caution in patients who may be at increased risk for GI perforation.

Adverse Reactions
Most common adverse reactions (>10% of patients) included rash, pruritus, upper respiratory tract infection, increased weight, and hyperuricemia.

Drug Interactions

Cytochrome P450 Substrates
Upon initiation or discontinuation of SYLVANT, in patients being treated with CYP450 substrates with a narrow therapeutic index, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) as needed and adjust dose. The effect of SYLVANT on CYP450 enzyme activity can persist for several weeks after stopping therapy. Exercise caution when SYLVANT is co-administered with CYP3A4 substrate drugs where a decrease in effectiveness would be undesirable (e.g., oral contraceptives, lovastatin, atorvastatin).

Dosage and Administration
Administer SYLVANT 11 mg/kg over 1 hour as an intravenous infusion every 3 weeks until failure.

Perform hematology laboratory tests prior to each dose of SYLVANT therapy for the first 12 months and every 3 dosing cycles thereafter. If treatment criteria outlined in the Prescribing Information are not met, consider delaying treatment with SYLVANT. Do not reduce dose.

Do not administer SYLVANT to patients with severe infections until the infection resolves.

Discontinue SYLVANT in patients with severe infusion related reactions, anaphylaxis, severe allergic reactions, or cytokine release syndromes. Do not reinstitute treatment.
SYLVANT® (siltuximab) BRIEF SUMMARY OF PRESCRIBING INFORMATION

CONTRAINdications
Severe hypersensitivity reaction to siltuximab or any of the excipients in SYLVANT. Hypersensitivity reactions, including anaphylactic reaction, hypersensitivity, and drug hypersensitivity have been reported in patients treated with siltuximab.

WARNINGS AND PRECAUTIONS

Concurrent Active Severe Infections
Do not administer SYLVANT to patients with severe infections until the infection resolves. SYLVANT may mask signs and symptoms of acute inflammation including suppression of fever and of acute Phase reactants such as C-reactive protein (CRP). Monitor patients receiving SYLVANT closely for infections. Institute prompt anti-infective therapy and do not administer further SYLVANT until the infection resolves.

Vaccinations
Do not administer live vaccines to patients or infants born to patients receiving SYLVANT because IL-6 inhibition may interfere with the normal immune response to new antigens.

Infusion Related Reactions and Hypersensitivity
SYLVANT may cause infusion related reactions and anaphylaxis. Symptoms of infusion reactions consisted of back pain, chest pain or discomfort, nausea and vomiting, flushing, erythema, and palpitations.

Stop the infusion of SYLVANT if the patient develops signs of anaphylaxis. Discontinue further therapy with SYLVANT.

Stop the infusion if the patient develops a mild to moderate infusion reaction. If the reaction resolves, the SYLVANT infusion may be restarted at a lower infusion rate. Consider medication with antihistamines, acetaminophen, and corticosteroids. Discontinue SYLVANT if the patient does not tolerate the infusion following these interventions.

Administer SYLVANT in a setting that provides resuscitation equipment, medication, and personnel trained to provide resuscitation.

Gastrointestinal Perforation
Gastrointestinal (GI) perforation has been reported in clinical trials although not in MCD trials. Use with caution in patients who may be at increased risk for GI perforation. Promptly evaluate patients presenting with symptoms that may be associated or suggestive of GI perforation.

ADVERSE REACTIONS

Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Study 1, in MCD, was an international, multicenter, randomized Phase 2 study of every 3 week infusions comparing SYLVANT and best supportive care (BSC) to placebo and BSC. The patients randomized to SYLVANT (n=53) received a median of 19 infusions (range 1 to 50) compared to patients randomized to placebo (n=26) who received a median of 8 infusions (range 2 to 32). To control for disparate exposure between arms, patient incidence of adverse reactions that occurred during the first 8 infusions are reported.

The most common adverse reactions (> 10%) during treatment with SYLVANT and BSC vs placebo vs BSC in the MCD clinical trial were rash (28% vs 12%), pruritus (28% vs 8%), upper respiratory tract infection (26% vs 15%), edema (generalized and local (26% vs 27%), hyperuricemia (11% vs 0%), and increased weight (19% vs 0%).

Study 2 was an open label, long term extension study of patients with MCD treated on prior trials. The median duration of siltuximab treatment was 5.52 years (range: 0.8 to 10.8 years); more than 50% of patients received siltuximab treatment for ≥5 years. The rate of serious or Grade ≥3 adverse events did not increase over time as a function of cumulative exposure.

Other important adverse reactions reported in MCD clinical studies, all of which were very common, were nasopharyngitis, urinary tract infection, neutropenia, dizziness, hypertension, nausea, abdominal pain, vomiting, diarrhea, gastroesophageal reflux disease, mouth ulceration.

ImmunoGenicity
A total of 432 patients across the clinical studies were evaluated at multiple time points for anti-therapeutic antibody (ATA) responses to siltuximab after treatment with SYLVANT. None of these patients had neutralizing antibodies. The clinical significance of anti-siltuximab antibodies following treatment with SYLVANT is not known.

Drug Interactions

Cytochrome P450 Substrates
Inhibition of IL-6 signaling in patients treated with SYLVANT may restore CYP450 activities to higher levels leading to increased metabolism of drugs that are CYP450 substrates compared to metabolism prior to treatment with SYLVANT.

Upon initiation or discontinuation of SYLVANT in patients being treated with CYP450 substrates with a narrow therapeutic index, perform therapeutic monitoring of effect (e.g., warfarin) or drug concentration (e.g., cyclosporine or theophylline) as needed and adjust dose. The effect of SYLVANT on CYP450 enzyme activity can persist for several weeks after stopping therapy. Exercise caution when SYLVANT is co-administered with CYP3A4 substrate drugs where a decrease in effectiveness would be undesirable (e.g., oral contraceptives, lovastatin, atorvastatin).

USE IN SPECIFIC POPULATIONS

Pregnancy
Monoclonal antibodies are transported across the placenta as pregnancy progresses, with the largest amount transferred during the third trimester. Infants born to pregnant women treated with SYLVANT may be at increased risk of infection. Consider the risks and benefits of administering live or live-attenuated vaccines to infants exposed to SYLVANT in utero.

Lactation
Because of the potential for serious adverse reactions in the breastfed child including gastrointestinal perforations, advise patients that breastfeeding is not recommended during treatment with SYLVANT, and for 3 months after the last dose.

Females and Males of Reproductive Potential
SYLVANT may cause embryo-fetal harm when administered to pregnant women. Advise female patients of reproductive potential to use effective contraception during treatment with SYLVANT and for 3 months after the last dose.

Pediatric Use
The safety and efficacy of SYLVANT have not been established in pediatric patients.

Geriatric Use
No differences in the safety profile between the elderly and younger patients were identified, but greater sensitivity of some older individuals cannot be ruled out.

Patients with Renal Impairment
Based on a population pharmacokinetic analysis using data from clinical trials in patients, no significant difference in siltuximab clearance was observed in patients with pre-existing renal impairment (creatinine clearance (ClCr) ≥ 15 ml/min) compared to patients with baseline normal renal function (ClCr ≥ 90 ml/min).

Patients with Hepatic Impairment
Based on a population pharmacokinetic analysis using data from clinical trials in patients, no significant difference in siltuximab clearance was observed in patients with pre-existing mild to moderate hepatic impairment (Child-Pugh Class A and B, respectively) compared to patients with baseline normal hepatic function. Patients with baseline severe hepatic impairment (Child-Pugh Class C) were not included in clinical trials.
### Platinum Level Sponsors
- Eisai Inc.
- GSK
- Incyte Corporation

### Gold Level Sponsors
- Janssen Oncology
- Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.

### Silver Level Sponsor
- Regeneron Pharmaceuticals

### Bronze Level Sponsors
- AstraZeneca
- Galera Therapeutics
- Jazz Pharmaceuticals, Inc.
- Sanofi Genzyme
- Servier
- Teva Oncology
NCCN Patient Advocacy Pavilion Sponsors

<table>
<thead>
<tr>
<th>Ruby</th>
<th>Genentech</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Lilly</td>
</tr>
<tr>
<td></td>
<td>Pharmacyclics, an AbbVie Company and Janssen Biotech, Inc.</td>
</tr>
<tr>
<td>Emerald</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td></td>
<td>Celgene Corporation</td>
</tr>
<tr>
<td></td>
<td>Coherus BioSciences</td>
</tr>
<tr>
<td></td>
<td>Dendreon</td>
</tr>
<tr>
<td></td>
<td>Eisai Inc.</td>
</tr>
<tr>
<td></td>
<td>Incyte Corporation</td>
</tr>
<tr>
<td></td>
<td>Invitae</td>
</tr>
<tr>
<td></td>
<td>Janssen Oncology</td>
</tr>
<tr>
<td></td>
<td>Jazz Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td></td>
<td>Karyopharm Therapeutics Inc.</td>
</tr>
<tr>
<td></td>
<td>Kite, a Gilead Company</td>
</tr>
<tr>
<td></td>
<td>Oncopeptides</td>
</tr>
<tr>
<td></td>
<td>Taiho Oncology</td>
</tr>
<tr>
<td>Topaz</td>
<td>AmerisourceBergen</td>
</tr>
<tr>
<td></td>
<td>Astellas Pharma US Inc.</td>
</tr>
<tr>
<td></td>
<td>GSK</td>
</tr>
<tr>
<td></td>
<td>Heron Therapeutics, Inc.</td>
</tr>
<tr>
<td></td>
<td>Natera</td>
</tr>
</tbody>
</table>

Exhibitor Showcase Presentation Schedule*

**Friday, March 20, 2020**

9:25 – 9:55 AM

Current Considerations in Selecting Androgen Deprivation Therapy (ADT) in Treatment of Advanced Prostate Cancer (APC)

*Presented by Ferring Pharmaceuticals Inc.*

3:25 – 3:55 PM

The Importance of PIK3CA Mutations in HR+/HER2- Advanced Breast Cancer

*Presented by Novartis*

**Saturday, March 21, 2020**

9:15 – 9:45 AM

A Therapeutic Option For R/R DLBCL, NOS, After At Least Two Prior Therapies: Study Results From a Randomized Trial

*Presented by Genentech*

3:15 – 3:45 PM

Transforming the Treatment of NSCLC: Options for First-Line Treatment of Metastatic EGFR Mutation-Positive Disease and Immunotherapy for Stage III Unresectable Disease

*Presented by AstraZeneca*

* Seating is open for all conference attendees in the Exhibitor Showcase area in the NCCN Exhibition Hall. No pre-registration required.
Visit our exhibit to learn more
Seeking answers to some of the most challenging questions in cancer research

**CANCER EPIGENETICS**
- How can we target specific epigenetic pathways to treat cancer?
- What epigenetic changes drive cancer development and progression?

**ONCOLOGY CELL THERAPY**
- Can a patient’s own immune cells be modified with redirected specificity to treat their cancer?
- Which targeted receptors have the most potential impact on tumor cells?

**SYNTHETIC LETHALITY**
- Which pathways are required for detection, repair, and bypass of DNA damage in cancer cells?
- How can we interfere with maladaptive DNA repair processes to inhibit tumor growth?

**IMMUNO-ONCOLOGY**
- How can we harness the body’s own immune system to attack cancer?
- Which drugs, alone or in combination, have the greatest potential to reduce treatment resistance and provide the most durable response?

©2020 GSK group of companies or its licensor. All rights reserved. February 2020.

**LIBTAYO**
(cemiplimab-rwlc)
Injection 350 mg

Explore the clinical profile of LIBTAYO
Visit booth #807 or LIBTAYOhcp.com to learn more

© 2019 Regeneron Pharmaceuticals, Inc., and sanofi-aventis U.S. LLC. All rights reserved. LIB.20.01.0027 01/20
Exhibition Hall

Exhibitors:
Abbvie ........................................ 810
Acceleron Pharma .......................... 342
ACOG/CDC Early Onset Breast Cancer Provider Education ....... 504
Acrotech Biopharma .......................... 445
Amp Gen Oncology ........................... 566
Astellas Pharma US Inc. ..................... 622
AstraZeneca ................................ 552
Athenex Oncology ........................... 558
Daichi Sankyo, Inc. ........................ 820
Datar Cancer Genetics Limited ......... 403
Dendreon ...................................... 503
Eisai Inc. ................................. 720
EUSA Pharma ................................ 507
Exelixis, Inc. ................................. 560
Ferring Pharmaceuticals Inc. ............ 310
Genentech ...................................... 305
GenPath Oncology ............................ 562
GSK ........................................... 668
* H. Lee Moffitt Cancer Center ............. 346
Harborside ..................................... 166
Icyte Corporation........................... 710
Ipsen Biopharmaceuticals, Inc. .......... 662
Janssen Biotech, Inc. ....................... 814
Jazz Pharmaceuticals, Inc. ................. 554
Karyopharm Therapeutics Inc. .......... 303
Kite Pharma, A Gilead Company ........ 660
LeanTaaS ........................................ 408
Merck & Co., Inc. ........................... 115
Natera ........................................... 343
Neovar (SiParadigm) .......................... 664
Novartis ......................................... 214
Novartis Medical Information ............. 164
Novocure Inc. .................................. 442
Oncology Nutrition
Dietetic Practice Group ...................... 111
Pacific Edge Diagnostics .................... 109
Pfizer ........................................... 240
Regeneron Pharmaceuticals ............. 807
Sanofi Genzyme ................................ 808
Seattle Genetics ............................... 812
Servier ........................................... 610
Spectrum Pharmaceuticals, Inc. ....... 607
* Stanford Health Care – Oncology ... 216
Taiho Oncology, Inc. .......................... 406
Takeda .......................................... 307
Teva Pharmaceuticals .......................... 608

Health Information Technology (HIT) Row
CRA Health .................................... 602
CureMD ......................................... 440
CVS Specialty ................................ 230
Equecraft Health .............................. 200
Flaticon Health .............................. 802
Mckesson Health ............................. 340
Naviagin Cancer ............................ 443
Optum ........................................... 550
Outcomes4Me Inc. .......................... 150
PatientPoint .................................. 401
Roche Diagnostics Corporation - NAVIFY Decision Support
Portfolio ..................................... 700
Siemens Healthineers ....................... 101
Varian Medical Systems .................... 650

Reimbursement Resource Room
Participants
BMS Access Support ....................... R9
Exact Sciences ............................... R2
Exelixis Access
Services – EASE ............................. R8
IncyteCARES ................................ R3
LIBTAYO Surround ®
Resource Center ........................... R4
myBeiGene™ Patient Support Program .... R6
Novartis Oncology –
Patient Assistance Now Oncology
(PANO) ........................................ R11
Takeda Oncology 1Point ..................... R1
TerSera .......................................... R5
Teva Oncology: CORE
(Comprehensive Oncology
Reimbursement Expertise) ................ R7
Xtandi Support Solutions ................. R10

Patient Advocacy Pavilion
Aanal Cancer Foundation ................. A13
BAG IT ......................................... A6
Cancer Hope Network ...................... A7
Colon Cancer Foundation ............... A17
Colorectal Cancer Alliance ............. A8
Fight Colorectal Cancer ................. A18
International Myeloma
Foundation (IMF) ........................ A16
International Waldenstrom’s
Macroglobulinemia
Foundation (IWMF) ...................... A14
Kidney Cancer Association .......... A9
The Leukemia &
Lymphoma Society ....................... A12
LUNGevity Foundation ................. A5
Lymphoma Research
Foundation .................................. A3
Nicki Leach Foundation ................. A2
NTD TV
(New Tang Dynasty Television) ........ A1
OneClickFund.com ....................... A4
PALTOWN Development
Foundation ......................... A15
Patient Empowerment
Network (PEN) .......................... A10
Sharsheret ................................. A11
Triage Cancer ............................... A19

Visit the NCCN & NCCN Foundation
Booth .......................................... #120

• Enter to Win Drawings – Drop off completed NCCN Trends Survey form and Poster Session forms (forms in conference bag)

• Receive a Complimentary Gift† –
Drop off completed NCCN Trends Survey or an Exhibitor Passport
(forms in conference bag)

• Meet for the “Follow the Expert”
Guided Poster Tours (see more information on page 30)

• Learn about upgrades to the NCCN
Guidelines Apps and gather patient resources

†While supplies last

*NCCN Member Institutions
Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do from early research to product development.

Change the world with us

kitepharma.com
Focused on the cure

Kite, a Gilead company, is dedicated to achieving one of the most ambitious goals of 21st century medicine: curing cancer. This mission is at the heart of everything we do from early research to product development.

Change the world with us

kitepharma.com
A NEW TREATMENT

PADCEV™
enfortumab vedotin-ejfv
Injection for IV infusion 20 mg & 30 mg vials

NOW FDA APPROVED

VISIT US AT:
ASTELLAS BOOTH #622
SEATTLE GENETICS BOOTH #812

PADCEVhcp.com
There is no routine cancer.

Just like no two people are exactly the same, neither are their cancers. Each patient’s cancer is fueled by different, unique elements that help cancer cells develop, survive, invade and grow. That’s why researchers and oncologists at The James study the unique genetic makeup of each patient’s cancer. As they discover what drives a patient’s cancer, they develop and deliver the most advanced targeted treatments, leading to better outcomes, faster responses, fewer side effects and more hope. To learn more, visit cancer.osu.edu.

The James

The Ohio State University
Weiner Medical Center
KidneyCancerAssociation™

Strong Alone. Unstoppable Together.

We’re proud to sponsor the NCCN Guidelines for Patients®: Kidney Cancer, 2020

Visit us at Booth A9 in the Patient Advocacy Pavilion in the Exhibit Hall

kidneycancer.org | kidneycancer | #unstoppabletogether
What's in the bag:

- Top resource publications
- A customizable *My Companion Guidebook* that helps patients organize and access their medical information

What the bag means to your practice:

- Saves time and costs by compiling resources into a single toolkit
- Helps practices meet accreditation guidelines
- Improves patient adherence to treatment and supports better outcomes

Patient education focusing on self-advocacy and survivorship through the continuum of care

---

**SPECTRUM IS COMMITTED TO THE FIGHT AGAINST CANCER**

Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted drug products, with a primary focus in oncology.

We are committed to excellence and have a passion to identify and develop important options for patients.

Corporate Office: 11500 South Eastern Avenue, Suite 240 | Henderson, NV 89052 | Tel: 702.835.6300
Research & Development: 157 Technology Drive | Irvine, CA 92618 | Tel: 949.788.6700

www.sppirx.com | info@sppirx.com | NASDAQ: SPPI
Health Information Technology Row

CRA Health  Booth # 602
CRA Health is breaking down barriers in the identification and management of patients at high-risk for breast cancer across many care settings. With over 15 years providing risk assessment, we now help care for 2,000,000 patients annually. We provide a comprehensive and targeted assessment that reflects your clinical objectives delivered with core strengths for EHR, Density/AI, and laboratory systems integration. Elevate the standard of care for your patients with our high-quality risk assessment program.

CureMD  Exhibit # 440
CureMD Oncology is the leading All-in-One EHR, Practice Management and Billing Services solution that provides NCCN Template library powered chemotherapy ordering, with links to NCCN Guidelines. It features decision support systems for dose calculations, medication administration record, automatic charge capture, clearing house, mobile-EMR and Check-in KIOSK. Our ASCO CancerLinQ® integration provides important clinical quality insights leading to improved outcomes. Learn more @www.curemd.com/oncology/ to find out why CureMD is the premier choice for Hematology-Oncology practices.

CVS Specialty  Booth # 230
Our commitment to helping patients and their physicians manage complex drug therapies by delivering expert individualized care and unmatched, multi-channel access has made us one of the leading specialty pharmacies in the country. We provide a full-range of pharmaceutical care, dispensing the latest FDA-approved medications.

Equicare Health  Booth # 200
Equicare Health is the industry’s leading provider of comprehensive care coordination solutions. EQUICARE CS™ is a web-based software tool that facilitates patient engagement including patient reported outcomes, patient navigation, survivorship care and other clinical tools like MDT, clinical trials, etc. Equicare offers an administrative suite of worklists and reports for managing adherence to many accreditation standards. ECS enables cancer centers to influence clinical outcomes for patients, optimize revenue streams and increase operational efficiency.

Flatiron Health  Booth # 802
Flatiron Health is a healthcare technology and services company focused on accelerating cancer research and improving patient care. Our platform enables cancer researchers and care providers to learn from the experience of every patient. Currently, Flatiron partners with over 280 community cancer practices, seven major academic research center, and over 15 of the top therapeutic oncology companies. For more information, please visit www.flatiron.com or follow us @FlatironHealth.

McKesson  Booth # 340
At McKesson, we clear the path so you can care for your patients. The health of your specialty practice goes beyond pharmaceutical distribution, and so does our support. We work with you to understand your entire business and offer ways to achieve your unique goals. We enable you to run your practice your way while increasing your efficiency, reimbursement and time for patient care. Our broad portfolio of provider solutions and services can’t be matched.

Navigating Cancer  Booth # 443
Navigating Cancer is the leader in patient relationship management software for cancer care. This patient-centered oncology platform puts the patient at the center of their own care and enables the care team to provide coordinated and comprehensive care at a lower cost. The platform enables providers to gain efficiencies in their care, meet value- based care initiatives, improve medication adherence and reduce hospitalizations for cancer patients.

Optum  Booth # 550
Optum Cancer Guidance Program (CGP) is an evidence-based cancer treatment, utilization management and analytics service to help Payers and Employers reduce the medical expenses associated with a range of high cost, complex cancer treatments. This comprehensive solution includes an online portal that helps providers obtain authorizations quickly and easily. It also provides extensive analytics and reporting to encourage better decision making.

Outcomes4Me Inc.  Booth # 150
Outcomes4Me is on a mission to improve health outcomes by providing a personalized, expert-validated evidence-based experience for patients. By delivering a complete view of their personal clinical information and up-to-date, clinically-validated treatment options, the Outcomes4Me platform empowers patients with their own care facilitating informed decision making and care management. Our technology-based solution combines patient input with clinical data to generate the real-world evidence necessary to drive future clinical decisions and improve outcomes.

PatientPoint  Booth # 401
PatientPoint™ is a patient engagement solutions company passionately committed to making every doctor-patient engagement better™. Learn more at www.patientpoint.com.

Roche  Booth # 700
As the world’s largest biotech company, Roche is focused on advancing science to improve people’s lives. The NAVIFY clinical decision support platform helps multi-disciplinary care teams navigate increasingly complex medical information and empowers them with holistic and actionable data. The first commercially available product in the portfolio is NAVIFY Tumor Board, a cloud-based software solution that changes the way oncology care teams prepare for conduct and document clinical treatment decisions.

Siemens Healthineers  Booth # 101
Siemens Healthineers offers products and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, molecular medicine, digital health services and enterprise services. Our solution AI-Pathway Companion leverages data integration and artificial intelligence to support multidisciplinary teams to ease diagnosis and treatment decisions and may enable personalized and standardized patient management and plans to offer process improvement insights through analysis of key performance indicators supporting patient-centric diagnosis and treatment decisions along disease-specific care pathways.

Varian Medical Systems  Booth # 650
Imagine a world free from the fear of cancer. We do, every day. That’s why at Varian, we’re obsessed with creating simpler, more efficient, and more effective technologies to power new victories in cancer care. Varian is the long-standing global leader in comprehensive solutions for radiotherapy and radiosurgery, as well as software systems for managing cancer clinics, sharing knowledge and using data to deliver evidence-based care.
Patient Advocacy Pavilion

Anal Cancer Foundation  Kiosk # A13
The Anal Cancer Foundation is a donor-supported research, support and advocacy non-profit organization. The Foundation empowers anal cancer patients and accelerates prevention and treatment methods to eliminate anal cancer and the virus that causes it and other cancers, HPV.

BAG IT  Kiosk # A6
Bag It is a patient education resource focusing on self-advocacy and survivorship. It contains a customizable binder (My Companion Guidebook) to help patients organize, navigate and access their medical information. There is reliable printed information on a variety of critical topics from national cancer organizations. The bag, available in both English and Spanish, helps patients and their families have the knowledge and confidence to be their own best advocate for their best quality of life.

Cancer Hope Network  Kiosk # A7
Cancer Hope Network provides free one-on-one emotional support to adult cancer patients and their loved ones. Each of CHN’s 400+ volunteers is at least one year post-treatment or successfully undergoing maintenance therapies. They have faced more than 80 cancer types and speak 15 languages. Our volunteers offer support from diagnosis, through treatment and into recovery. Each match is overseen by our professional Programs Team. CHN serves clients in the United States and Canada.

Colon Cancer Foundation  Kiosk # A17
The Colon Cancer Foundation – Our vision is A World Without Colorectal Cancer™. Our mission is to lead the fight against colorectal cancer (CRC) by promoting prevention through community awareness and education, leading advocacy efforts focused on improving the quality of life of patients, their families and caregivers and supporting colon and rectal cancer research initiatives.

Colorectal Cancer Alliance  Kiosk # A8
Colorectal Cancer Alliance is a national nonprofit committed to ending colorectal cancer within our lifetime. We empower a nation of passionate survivors and advocates to help patients and caregivers navigate diagnosis and treatment, and we serve as allies with healthcare professionals—those who understand the value of early detection. Partnering with doctors and nurses around the country, we are working urgently to raise awareness of preventive screening because we believe tomorrow can’t wait. #tomorrowscanwait #nationofallies ccalliance.org

Fight Colorectal Cancer  Kiosk # A18
The leading patient advocacy organization focused on providing patient education, impactful policy change, and research endeavors.

International Myeloma Foundation (IMF)  Kiosk # A16
The International Myeloma Foundation (IMF) is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure through our 4 founding principles: Research, Education, Support, and Advocacy.

International Waldenstrom’s Macroglobulinemia Foundation (IWMF)  Kiosk # A14
The International Waldenstrom’s Macroglobulinemia Foundation (IWMF) is a patient-founded and volunteer-led nonprofit organization dedicated to a simple but compelling mission: Support and education everyone affected by Waldenstrom’s Macroglobulinemia (WM) while advancing the search for a cure.

Kidney Cancer Association  Kiosk # A9
The Kidney Cancer Association is a global community dedicated to serving and empowering patients and leading change through advocacy, research, and education in order to be the universal leader in the cure for kidney cancer.

The Leukemia & Lymphoma Society  Kiosk # A12
The Leukemia & Lymphoma Society (LLS) is the world’s largest voluntary health agency dedicated to blood cancer. The LLS mission: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families. LLS funds lifesaving blood cancer research around the world and provides free information and support services. www.LLS.org/PatientSupport.

LUNGevity Foundation  Kiosk # A5
LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as providing community, support, and education for all those affected by the disease.

Lymphoma Research Foundation  Kiosk # A3
The Lymphoma Research Foundation’s mission is to eradicate lymphoma and serve those impacted by this blood cancer.

Nicki Leach Foundation  Kiosk # A2
The mission of the Nicki Leach Foundation is to honor Nicki’s request and help young adults, (AYA’s) who have cancer so they can continue their educational dreams and goals, we do this through endowed scholarships for their education. We also help fund cancer research involving Adolescents & Young Adults between the ages of 18-39 hoping to find better treatments and cures. Nicki lost her life to cancer (glioblastoma) brain tumor at 19.

NTD TV  Kiosk # A1
NTD TV is a 501c(3) TV broadcaster founded in 2001. Headquartered in New York City, NTD is committed to helping new immigrants integrate into American society and to help to address the growing need from the Chinese and Asian immigrants’ community to access health and medical information.

OneClickFund.com  Kiosk # A4
Patients First. OneClickFund.com provides support for patients and caregivers and funding for kidney cancer research.

PALTOWN Development Foundation  Kiosk # A15
GROWING Patient-Powered Disease-Specific Communities. TRAINING & EMPOWERING Patient Leaders.

Patient Empowerment Network (PEN)  Kiosk # A10
Patient Empowerment Network’s (PEN) mission is to fortify cancer patients and care partners with knowledge and tools to boost their confidence, put them in control of their healthcare journey, and assist them with receiving the best, most personalized care available. Our programs focus on enhancing health literacy to enable shared decision-making and providing information and educational resources to help patients consider clinical trials as an option throughout treatment.

Sharsheret  Kiosk # A11
Sharsheret is a national not-for-profit organization that provides free psychosocial support to women facing breast and ovarian cancers or genetic mutations that raise diagnostic risk, Sharsheret also provides free cultural competency training to staff of cancer centers throughout the country. For more information or to learn about how our programs and help your patients, visit us at www.sharsheret.org or call us at (866) 474-2774.

Triage Cancer  Kiosk # A19
Triage Cancer is a national, nonprofit organization that provides education on the practical and legal issues that may impact individuals diagnosed with cancer and their caregivers, through events, quick guides, and cancer resources.
About Our Exhibitors

AbbVie Booth # 810
At AbbVie, we strive to discover and develop medicines that deliver transformational improvements in cancer treatment by uniquely combining our deep knowledge in core areas of biology with cutting-edge technologies, and by working together with our partners – scientists, clinical experts, industry peers, advocates, and patients. We remain focused on delivering these transformative advances in treatment across some of the most debilitating and widespread cancers. We are also committed to exploring solutions to help patients obtain access to our cancer medicines. AbbVie’s oncology portfolio now consists of marketed medicines and a pipeline containing multiple new molecules being evaluated worldwide in more than 300 clinical trials and more than 20 different tumor types. For more information, please visit www.abbvie.com/oncology.

Acrotech Biopharma Booth # 445
Founded in 2018, Acrotech Biopharma LLC, was formed as a global platform to commercialize innovative proprietary medications. The company aims to launch scientifically advanced products to address unmet needs and deliver value to patients as well as all healthcare stakeholders. Acrotech aspires to be a patient focused, research-based organization that strives to launch treatments which are accessible to patients that need them.

Amgen Oncology Booth # 566
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. A biotechnology pioneer since 1980, Amgen has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Astellas Pharma US Inc. Booth # 622
Astellas Pharma US, Inc., is a U.S. affiliate of Tokyo-based Astellas Pharma Inc. Located in Northbrook, Illinois, the company serves as the headquarters for the Americas and employs nearly 3,000 people. Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products.

Athenex Oncology Booth # 558
Athenex is a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies to treat cancer. Our mission is to improve the lives of cancer patients by creating more effective, safer, and tolerable treatments. Our clinical pipeline drugs are based on our understanding of human absorption biology and novel approaches to inhibiting kinase activity. Our ability to overcome the challenges of oral delivery of chemotherapy and convert cornerstone therapies to the oral route offers significant potential benefits to patient outcomes.

Daiichi Sankyo, Inc. Booth # 820
Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is the U.S. subsidiary of Daiichi Sankyo Co., Ltd. Daiichi Sankyo, Inc. is a member of the Daichi Sankyo Group and is focused on the development of oncology therapies and specialty medicines. Daiichi Sankyo, Inc. medicines approved in the U.S. include therapies for hypertension, pain management, dyslipidemia, diabetes, thrombosis, stroke risk reduction, acute coronary syndrome, opioid-induced constipation, IV iron therapy and metastatic melanoma.

Datar Cancer Genetics Limited Booth # 403
Datar Cancer Genetics specializes in research based molecular/genomic analysis pertaining to cancer. Datar has a modern, fully integrated facility for molecular pathology, genetic and tissue investigation, spread over more than 30,000 sq. ft. The Datar Team comprises of very well qualified and experienced molecular biologists / scientists / pathologist / clinicians and is over 210 strong. Datar’s facility is accredited for quality by the College of American Pathologists (CAP), CLIA (US Government), ILAC-NABL and TUV for compliance to relevant medical reporting standards.

Dendreon Booth # 503
Founded on the belief that immunotherapy made from a patient’s own cells will transform cancer treatment, Dendreon fights for patients by making the battle against cancer personal. By harnessing the power of the body’s immune system, we help extend the lives of patients battling cancer. Our flagship product, PROVENGE® (sipuleucel-T), was the first FDA-approved immunotherapy made from a patient’s own immune cells. Since 2010, nearly 30,000 men with advanced prostate cancer have been prescribed PROVENGE.

Eisai Inc. Booth # 720
As the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., our passionate commitment to patient care is the driving force behind our efforts to help address unmet medical needs. We are a fully integrated pharmaceutical business with discovery, clinical, and marketing capabilities. Our key areas of focus include oncology and neurology (dementia-related diseases and neurodegenerative diseases). To learn more about Eisai Inc., please visit us at www.eisai.com/US and follow us on Twitter and LinkedIn.

EUSA Pharma Booth # 507
EUSA Pharma is a dynamic, global biopharmaceutical company focused on oncology and rare disease, continuously striving to confront gaps in patient care. Our ambition drives us to deliver medical treatments that deliver real change to improve lives wherever they are needed in the world. As a young, specialty pharmaceutical company, EUSA Pharma is committed to delivering solutions that can have a meaningful effect on life, helping patients across a range of therapy areas. www.eusapharma.com
Exelixis, Inc.  Booth # 560
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. We are supplementing our existing therapeutic assets with targeted business development activities and internal drug discovery – all to deliver the next generation of Exelixis medicines and help patients recover stronger and live longer. www.exelixis.com

Ferring Pharmaceuticals Inc.  Booth # 310
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive medicine, maternal health, urology, gastroenterology, endocrinology, orthopaedics and oncology. For more information, visit www.FerringUSA.com

Genentech  Booth # 305
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.

GenPath Oncology  Booth # 562
GenPath, a division of BioReference Laboratories, Inc., is a full service oncology/pathology laboratory with over 15 years of diagnostic experience. GenPath employs specialized pathologists and offers a comprehensive test menu. From routine clinical and special coagulation testing to complex genomic testing for tumor sequencing and hereditary cancer syndromes, the full spectrum of a cancer patient work-up is covered in one laboratory. BioReference Laboratories, Inc. is a wholly owned subsidiary of OPKO Health Inc.

Gold Sponsor
Janssen Biotech, Inc.  Booth # 814
At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts. For more information, visit www.janssen.com.

Platinum Sponsor
Incyte Corporation  Booth # 710
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Ipsen Biopharmaceuticals  Booth # 662
Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group focused on innovation and specialty care. The company is dedicated to providing hope for patients whose lives are challenged by difficult-to-treat diseases, focusing its resources, investments and energy on discovering, developing and commercializing new therapeutic options in oncology, neurosciences and rare diseases. For more information on Ipsen, please visit www.ipsenus.com.

Platinum Sponsor
Janssen Biotech, Inc.  Booth # 814
Janssen Biotech, Inc. is a research-driven biopharmaceutical company dedicated to identifying, developing and marketing innovative products in the fields of reproductive medicine, maternal health, urology, gastroenterology, endocrinology, orthopaedics and oncology. For more information, visit www.janssen.com.

Platinum Sponsor
Ipsen Biopharmaceuticals  Booth # 662
Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group focused on innovation and specialty care. The company is dedicated to providing hope for patients whose lives are challenged by difficult-to-treat diseases, focusing its resources, investments and energy on discovering, developing and commercializing new therapeutic options in oncology, neurosciences and rare diseases. For more information on Ipsen, please visit www.ipsenus.com.

Platinum Sponsor
Genentech  Booth # 305
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.

Platinum Sponsor
GenPath Oncology  Booth # 562
GenPath, a division of BioReference Laboratories, Inc., is a full service oncology/pathology laboratory with over 15 years of diagnostic experience. GenPath employs specialized pathologists and offers a comprehensive test menu. From routine clinical and special coagulation testing to complex genomic testing for tumor sequencing and hereditary cancer syndromes, the full spectrum of a cancer patient work-up is covered in one laboratory. BioReference Laboratories, Inc. is a wholly owned subsidiary of OPKO Health Inc.

About Our Exhibitors

Janssen Biotech, Inc.  Booth # 814
At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts. For more information, visit www.janssen.com.

Gold Sponsor
Janssen Biotech, Inc.  Booth # 814
At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts. For more information, visit www.janssen.com.

Platinum Sponsor
Incyte Corporation  Booth # 710
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Ipsen Biopharmaceuticals  Booth # 662
Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group focused on innovation and specialty care. The company is dedicated to providing hope for patients whose lives are challenged by difficult-to-treat diseases, focusing its resources, investments and energy on discovering, developing and commercializing new therapeutic options in oncology, neurosciences and rare diseases. For more information on Ipsen, please visit www.ipsenus.com.

Platinum Sponsor
Genentech  Booth # 305
Founded more than 40 years ago as the first biotechnology company, Genentech is dedicated to the rigorous pursuit of science and the development and delivery of life-changing medicines for people facing serious diseases. Headquartered in South San Francisco, California and a proud member of the Roche Group, our community is united by a common purpose and sense of urgency to transform the future of healthcare. Learn more at gene.com.

Platinum Sponsor
GenPath Oncology  Booth # 562
GenPath, a division of BioReference Laboratories, Inc., is a full service oncology/pathology laboratory with over 15 years of diagnostic experience. GenPath employs specialized pathologists and offers a comprehensive test menu. From routine clinical and special coagulation testing to complex genomic testing for tumor sequencing and hereditary cancer syndromes, the full spectrum of a cancer patient work-up is covered in one laboratory. BioReference Laboratories, Inc. is a wholly owned subsidiary of OPKO Health Inc.

Gold Sponsor
Janssen Biotech, Inc.  Booth # 814
At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts. For more information, visit www.janssen.com.

Platinum Sponsor
Incyte Corporation  Booth # 710
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Ipsen Biopharmaceuticals  Booth # 662
Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group focused on innovation and specialty care. The company is dedicated to providing hope for patients whose lives are challenged by difficult-to-treat diseases, focusing its resources, investments and energy on discovering, developing and commercializing new therapeutic options in oncology, neurosciences and rare diseases. For more information on Ipsen, please visit www.ipsenus.com.

Gold Sponsor
Janssen Biotech, Inc.  Booth # 814
At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts. For more information, visit www.janssen.com.

Platinum Sponsor
Incyte Corporation  Booth # 710
Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit Incyte.com and follow @Incyte.

Ipsen Biopharmaceuticals  Booth # 662
Ipsen Biopharmaceuticals, Inc. is the U.S. affiliate of Ipsen (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical group focused on innovation and specialty care. The company is dedicated to providing hope for patients whose lives are challenged by difficult-to-treat diseases, focusing its resources, investments and energy on discovering, developing and commercializing new therapeutic options in oncology, neurosciences and rare diseases. For more information on Ipsen, please visit www.ipsenus.com.

Gold Sponsor
Janssen Biotech, Inc.  Booth # 814
At Janssen Biotech, Inc. we have an urgent commitment to make a difference for cancer patients and those living with autoimmune diseases. Comprised of Janssen Oncology and Janssen Immunology, we deliver transformational biologic medicines to market, and have built a rich legacy of innovative firsts. For more information, visit www.janssen.com.
About Our Exhibitors

Natera | Booth # 343
Natera has developed Signatera, a personalized ctDNA test for molecular residual disease (MRD) detection and recurrence monitoring in patients previously diagnosed with cancer. Signatera’s tumor-informed assay is optimized to detect low levels of ctDNA, with high accuracy in detecting low levels of ctDNA and identifying MRD and recurrence with longer lead times. Signatera has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.

Pfizer | Booth # 240
At Pfizer Oncology, we are committed to advancing medicines wherever we believe we can make a meaningful difference in the lives of patients. Today, Pfizer Oncology has an industry-leading portfolio of 22 approved innovative cancer medicines and biosimilars across more than 30 indications, including breast, prostate, kidney and lung cancers, as well as leukemia and melanoma.

Silver Sponsor

Regeneron Pharmaceuticals | Booth # 807
Regeneron Pharmaceuticals is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. Since 2007, Sanofi & Regeneron have collaborated to develop & commercialize fully human monoclonal antibodies utilizing proprietary technologies.

Bronze Sponsor

Sanofi Genzyme | Booth # 808
Sanofi Genzyme, the specialty care global business unit of Sanofi, focuses on rare diseases, multiple sclerosis, oncology, and immunology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. Our approach is shaped by our experience developing highly specialized treatments and forging close relationships with physician and patient communities. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Learn more at www.sanofigenzyme.com.

Seattle Genetics | Booth # 812
Seattle Genetics is a global biotechnology company that discovers, develops and commercializes transformative cancer-targeting therapies. ADCETRIS® (brentuximab vedotin) and PADCEV™ (enfortumab vedotin-efv) use the company’s industry-leading antibody-drug conjugate technology designed to bring a powerful medicine directly to cancer cells. ADCETRIS is approved for the treatment of several types of CD30-expressing lymphomas, and PADCEV is approved to treat adults with metastatic urothelial cancer. For more information, visit www.seattlegenetics.com and follow @SeattleGenetics on Twitter.

Spectrum Pharmaceuticals, Inc. | Booth # 607
Spectrum Pharmaceuticals is a biopharmaceutical company focused on acquiring, developing, and commercializing novel and targeted oncology therapies. Spectrum has a strong track record of successfully executing across the biopharmaceutical business model, from in-licensing and acquiring differentiated drugs, clinically developing novel assets, successfully gaining regulatory approvals and commercializing in a competitive healthcare marketplace. Spectrum has a late-stage pipeline with novel assets that serve areas of unmet need. For additional information visit www.sppirx.com.

Takeda Oncology, Inc. | Booth # 406
Takeda Oncology, Inc. has built a world class clinical development organization that works urgently to develop innovative cancer treatments. Takeda is focused on bringing novel technology to cornerstone chemotherapies for a wide range of tumor types – including colorectal and gastric cancer and a variety of solid tumors.

Takeda | Booth # 307
The global oncology business unit of Takeda Pharmaceutical possesses a passion for improving patients’ lives, rooted in a strong heritage of science and innovation. We are changing expectations in science by focusing on treatments that address forms of cancer that haven’t traditionally been the focus of oncology R&D. Our mission is not simple but we are up to the task: We aspire to cure cancer.

Bronze Sponsor

Teva Pharmaceuticals | Booth # 608
Teva Pharmaceuticals is a global leader in generic medicines and biopharmaceuticals. Building on more than a century-old legacy, Teva delivers high-quality products to patients in nearly every therapeutic area, has an established presence in generics, specialty, OTC and API, a fully integrated R&D function, strong operational base and global infrastructure and scale.
LUNGevity has information and support that patients and caregivers need to make informed healthcare decisions. Visit www.LUNGevity.org to learn more.

Lung Cancer 101 is a comprehensive medically vetted online guide to understanding how lung cancer develops, how it can be detected, treatment options and what to expect. Download tips, booklets, and informational videos.

Experts Blog includes clear discussions about the latest developments in research and what they mean for patients.

Lung Cancer Navigator mobile app helps patients manage their healthcare. Lung Cancer HELPLine is a toll-free support service answered by oncology social workers. Call 844-360-LUNG.

Online Survivor and Caregiver Resource Centers help patients live well with lung cancer, and provide tip sheets with questions for visits with one’s medical team.

PEER-TO-PEER SUPPORT

LifeLine matches patients and caregivers to mentors who have had similar experiences, for personalized one-on-one support.

Clinical Trial Ambassadors are volunteers available to offer information about their personal experiences with clinical trials to fellow lung cancer patients.

Lung Cancer Support Community message boards provide patients and caregivers with peer-to-peer support and information.

The International Lung Cancer Survivorship Conference is a unique, weekend conference, designed by and for people diagnosed with lung cancer and their caregivers. The conference teaches attendees how to live well at all stages of a lung cancer diagnosis.

About LUNGevity Foundation

LUNGevity Foundation is firmly committed to making an immediate impact on increasing quality of life and survivorship of people with lung cancer by accelerating research into early detection and more effective treatments, as well as by providing community, support, and education for all those affected by the disease. For more information, please visit www.LUNGevity.org.

A blood cancer diagnosis can be overwhelming for your patients. Blood cancer patients, including those with leukemia, lymphoma and myeloma, can find hope, education, guidance and support from The Leukemia & Lymphoma Society (LLS).

Our Information Specialists complement the care you provide with FREE, in-depth personalized services that connect patients to financial assistance, patient education (including booklets, podcasts and webinars), online and in-person support, and the LLS Clinical Trial Support Center for assistance with clinical trials.

Patients and families can contact us at 800.955.4572 or go to www.LLS.org/patient-support.
Colorectal cancer is the second-leading cause of cancer-related deaths in the U.S.

We are a nation of passionate allies determined to end this senseless killer.

Join us at NationOfAllies.org

(877) 422-2030

Our vision:
A World without WM (Waldenstrom's macroglobulinemia).

Our mission:
Support and educate everyone affected by Waldenstrom's macroglobulinemia (WM) while advancing the search for a cure.

WWW.IWMF.COM

6144 Clark Center Ave. Sarasota, FL 34238
Phone 941-927-4963 Email Info@IWMF.com EIN: 54-1784426
Every day 400 people are diagnosed with colorectal cancer.

We collaborate with public and private organizations, academic institutions and community cancer centers around the world to bring that number to ZERO.

For more information on our Mission Partnerships and Programs stop by our Kiosk #A17

Dedicated to a World Without Colorectal Cancer™

www.coloncancerfoundation.org

The Anal Cancer Foundation

empowers anal cancer patients and accelerates prevention and treatment methods to eliminate anal cancer and the virus that causes the majority of cases, HPV.

The Foundation started in 2010 when three siblings, Justine, Tristan and Camille Almada, lost their wonderful mother Paullette to stage IV HPV-related anal cancer. When Paullette was diagnosed at the age of 51, her treatment options were the same as existed in 1974 and there were few medical or support resources for her to fight the disease. Since its founding, the organization has become a leader in the fight against anal cancer and HPV, which causes 5% of all cancers.

The Anal Cancer Foundation has achieved key milestones towards eradicating anal cancer and supporting patients including:

- Investing hundreds of thousands of dollars in novel scientific research for new treatments. In 2018, treatment guidelines were updated with a Foundation-funded immunotherapy that provides the first advance in metastatic anal cancer treatment in four decades.
- Establishing the first scientific medical society and network for anal cancer.
- Leading coalitions of disease and medical groups to ensure equal access to the cancer-preventing HPV vaccine.
- Creating the first educational forums and peer support program for anal cancer patients and caregivers.
- Educating clinicians about best practices to improve the anal cancer patient experience.

Please visit our website for the latest medical news on HPV and anal cancer. It is also a great support system for patients and their families. www.analcancerfoundation.org
KNOWLEDGE IS YOUR SUPERPOWER!

BUT WHERE DO YOU BEGIN?

Start with the Patient Empowerment Network, a non-profit, dedicated to giving cancer patients the knowledge and tools to:

- Boost your confidence,
- Put you in control of your healthcare journey
- Assist you in receiving the best, most personalized care

Our programs and resources are free to participants thanks to the support of our partners and donors.

Easily access medical experts, industry leaders, peers, patients, advocates, and curated resources addressing a broad range of topics.

Our Path to Empowerment empowers and educates you through each stage in the cancer journey, from the first office visit and testing, through life after treatment.

Sign up for our newsletter and follow us on social media for the latest in cancer developments, inspiring patient stories and easy-to-understand information for patients and care partners.

powerfulpatients.org @power4patients

We are supporting Adolescents & Young Adults (AYAs) with cancer, through research and endowed grants for education

"Nicki always found beauty in the world even in the worst of circumstances. When she knew her life here was ending, she gave me an assignment. She asked me to find a way to help others like I helped her. Nicki never stopped smiling." - Bunny Leach

The mission of the Nicki Leach Foundation is to honor Nicki's request to find a way to help young adults who have cancer. Nicki lost her life to cancer at 19.

We fund cancer research involving Adolescents & Young Adults (AYAs) between the ages of 15-39 who have cancer. In addition, the Nicki Leach Foundation helps provide endowed grants to support their educational goals. We see this as an unmet need.

Thank you for supporting our mission so that we can help AYAs achieve their educational goals and continue our efforts to find new treatments leading to cures for AYA cancers.

The Nicki Leach Foundation is a public nonprofit 501 (c) (3) Corporation. We depend on your support.

The Nicki Leach Foundation
190 Coastal Oak Circle
Ponte Vedra Beach, FL 32082
(904) 716-5394
www.nickileach.org
For nearly forty years, Cancer Hope Network Support Volunteers like those pictured above have been providing free and confidential one-on-one emotional peer support to adult cancer patients and their loved ones.

Each of our 400+ Support Volunteers is at least one year post-treatment or successfully undergoing maintenance therapies. They have faced more than 80 cancer types and speak 15 languages. They offer encouragement from diagnosis, through treatment and into survivorship.

For more information or to learn how we can support your patients and their caregivers, come see us in the Exhibit Hall, visit cancerhopenetwork.org or call 877-HOPENET.

877-HOPENET
CANCERHOPENETWORK.ORG

NTD provides Asian patients with in-language disease education through TV, print, digital, social and live events

- Nonprofit TV broadcaster
- Connection to Asian patients and physicians
- Dedication to public health and patient advocacy in the Asian community in US
- Multi-language services: Chinese, Korean, Vietnamese, Japanese and English

Visit our booth or email us at: health@ntdtv.com
Visit the International Myeloma Foundation (IMF) at the National Comprehensive Cancer Network annual conference at: Kiosk A16 (Located in the Patient Advocacy Pavilion)

The IMF is dedicated to improving the quality of life of myeloma patients while working toward prevention and a cure through our four founding principles: Research, Education, Support, and Advocacy.
Do You Know What You Need To KNOW?

CONTACT US TO SCHEDULE A TRAINING!
MROSEN@SHARSHERET.ORG
WWW.SHARSHERET.ORG

TRAININGS INCLUDE:
• The Impact of Culturally Competent Cancer Care
• Finding a New Normal: Helping Your Patients Manage Survivorship
• Hereditary Breast and Ovarian Cancers in the Jewish Community
• Coping with Cancer: A New Approach to Reduce Cancer-Related Stress in Patients
We can create additional trainings based on the specific needs of your health care team.

OneClickFund.com
<table>
<thead>
<tr>
<th>Poster #</th>
<th>Presenter and Institution</th>
<th>Title</th>
<th>Co-Authors</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>Karen Wonders, PhD</td>
<td>The Promotion of Exercise Oncology as a Standard Part of Clinical Practice</td>
<td>Rob Wise, BS; Danielle Ondreka, BS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>2</td>
<td>Lida Mina, MD</td>
<td>Hospitalization and Supportive Care Medication (BCM) Utilization Among Patients Treated with Talaizapar/pal (TALA) Multicenter: An Integrated Analysis of Five Clinical Trials (Phase 1-3) in Advanced Cancers</td>
<td>Ruben G.W. Quek, PhD; Johannes Ett, MD; Ying Chen, PhD; Miguel Martin, MD, PhD; Zev A. Warburg, MD, Johann S. de Bono, MD, Sara A. Hurvitz, MD; Hope S. Rugo, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>3</td>
<td>Sara A. Hurvitz, MD</td>
<td>Patient (Pt)-Reported Outcomes (PRO) in Patients with HER2-Negative Locally Advanced/Metastatic Breast Cancer (LamBC) and a Germline BRCA1/2 Mutation (gBRCA1/2) Receiving Talaizapar/pal Reversing Talaizapar/pal vs. Physician's Choice of Chemotherapy (PCT): A Focus on EMBRACA Racial Subgroups</td>
<td>Ruben G.W. Quek, PhD; Helen Bhattacharyya, PhD; Johannes Ett, MD; Anthony Gancak, MD; Elchin B. Mansurov, PhD; Hope S. Rugo, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>4</td>
<td>Elchin B. Mansurov, PhD</td>
<td>The Prognostic and Predictive Significance of Joint Investigation of Tumor Marker CA 15-3 and Vitamin D in Breast Cancer Patients</td>
<td>Jami A. Aliche, Swini E. Rahmzade, PhD; Azad A. Karimi, PhD; Leylakhemam A. Melikova, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>5</td>
<td>Elchin B. Mansurov, PhD</td>
<td>Role of TUBB3 Gene Expression in Early and Advanced Breast Cancer Stage Formulation: A Focus on TUBB3 Racial Subgroups</td>
<td>Swini E. Rahmzade, PhD; Azad A. Karimi, PhD; Leylakhemam A. Melikova, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>6</td>
<td>Elchin B. Mansurov, PhD</td>
<td>Characteristics of Gynecological Anamnesis and it's Prognostic Role in Azerbaijani Women with Breast Cancer</td>
<td>Jami A. Aliche, Elihak E. Kazimiro, MD; Leylakhemam A. Melikova, PhD; Turan E. Manasrova, MD; Swini E. Rahmzade, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>7</td>
<td>Elise James, LCSW, OSW-C</td>
<td>Utilization of a Distress Screening Tool in an Inpatient Hematopoietic Stem Cell Transplant Unit</td>
<td>Christina Pozzo-Kademian, PhD; Maritza Alencar, MD; AFRP-B; SMTCN; Jessica MacIntyre, MINI; AFRP, NP-C, AOCNP; Liza Machaud, LCSW; Abby-Gail Solomon, MSW; Michelle Rodriguez Diaz, PhD; Sophie Tenor, BA; Maria Rueda-Lara, MD; Hava Espinosa, AFRP-B</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>8</td>
<td>Jacob J. Adasheke, DO</td>
<td>Gene Silencing: Another Mechanism of Resistance?</td>
<td>Shumiie Kato, MD; Rahul Parulkar, BS; Christopher W. Szole, PhD; J. Zachary Sanborn, PhD; Charles J. Vasek, PhD; Stephen C. Benz, PhD; Sandeep K. Reddy, MD; Rassle Kurczok, MD</td>
<td>Correlative/Genomic</td>
</tr>
<tr>
<td>10</td>
<td>Trung Tat Ngo, PhD</td>
<td>Combinatory Use of Curing TERT Promoter Mutations and miR-122 Expression for Screening HBV-Related Hepatocellular Carcinoma</td>
<td>Le Huu Song, PhD</td>
<td>Pre-Clinical Oncology</td>
</tr>
<tr>
<td>11</td>
<td>Anthony Q. Yang, MD, MS</td>
<td>Baseline Assessment of Oncology Provider’s Quality Improvement Knowledge in a Multi-Institutional Breast Cancer Quality (BCQ) Grive</td>
<td>Ashley Byerley, MBA, MPH; Eileen Ngo, MPH; Julie K. Johnson, MSPh, MD; Karl Y. Bilimoria, MD, MS; Lindsey Krueger, MPH</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>12</td>
<td>Shawn Malone, MD</td>
<td>Impact of Treating Physician on Late Treatment Related Mortality – A Secondary Analysis of a Phase III Randomized Controlled Study in Localized Prostate Cancer</td>
<td>Scot Grucin, Sowmyraj Roy</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>13</td>
<td>Christine Neukirn, PhD</td>
<td>Years of Potential Life Lost Due to Cervical and Uterine Cancer Deaths in the United States, 2000-2016</td>
<td>Shely Corman, PharmD, MS, BCPS</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>14</td>
<td>Scott Paskett, MD</td>
<td>The Impact of Genetic Cancer Clinical Pathways Based on National Comprehensive Cancer Network Guidelines on Treatment Heterogeneity and Clinical Outcomes in the US Oncology Network</td>
<td>Curtis W. Mayes, PhD; Bemark Baldis, PhD; Astra M. Lips, PharmD; Anindya Chatterjee, PhD; Lisa M. Hess, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>15</td>
<td>Shivash Vishwakarma, PhD</td>
<td>Comparison of a Single Dose Immediate Inhibition of Mitomycin C 20mg Versus 40mg in Prevention of Tumour Recurrence After Resection of Non Muscle Invasive Bladder Cancer</td>
<td>Gird Kumar Posket, MS, MCh; George Mathew, MS, MCh</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>16</td>
<td>Sai-Ching Yeung, MD, PhD</td>
<td>Clinical Characteristics, Management and Outcome of Incidental Pulmonary Embolism in Cancer Patients: A Case-Control Study</td>
<td>Aham Qaish, MD; Mora Kamal, MD, PhD; Aisha Al-Saheli, MD; Biman Goswami, MD; Carol C. Wu, MD; Shouhao Zhou, PhD; Terry Rice, MD; Kumar Asapag, CA</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>17</td>
<td>Hai Ling Chen, BSN</td>
<td>Cancer Patients and Family Caregivers as a Unit of Care</td>
<td>Tsu-Sui Anae-Ko, PhD, FNP-BC</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>18</td>
<td>Ramon Mohanty, MD, PhD</td>
<td>Penbutal: A Potent Inducer of Hepatocellular Production for the Prevention of Tissue Injury Overload in Patients Receiving Blood Transfusion Chronically</td>
<td>Lan Huang, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>19</td>
<td>Yutaka Matsuoka, MD, PhD</td>
<td>Development of Cancer Survivorship Guidelines in Japan: An Expert Panel's Consensus</td>
<td>Ryo Okubo, MD, PhD; Yoichi Shimizu, INN, PhD; Katsumori Tsuch, PhD; Natsuyama Tominami, MA; Jisheik Sashik, MA; Hiroshi Sashik, MA</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>20</td>
<td>Ke Maung, MD</td>
<td>Retrospective Study of Safety and Toxicity Profile Comparison for Propylene Glycol Free Melphalan (Evan®) and Generic Melphalan</td>
<td>Nelson Jan An Chia, MD; Kelly Corbet, BA; Ashley Morris Engemann, PharmD; Cristina Gasparetti, MD; Mitchell Horwitz, MD; Yabin Kan, MD; Gayoom Douglas Long, MD; Richard D. Lopez, MD; David Rastori, MD; Stefane Sarkaropoulou, PhD; Keith M. Sullivan, MD; Anthony Derek Sunk, MD; Taewoong Choi, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>21</td>
<td>Tam Bui, MD</td>
<td>A Study of Pathological Characteristics of Clinical Proportional Proliferative Lesions</td>
<td>NA</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>Poster #</td>
<td>Presenter and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------</td>
<td>-------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>22</td>
<td>Mina Shensuda, MD</td>
<td>Genetic Testing for At-Risk Patients with Colorectal and/or Pancreatic Cancer at an Institution, A Quality Improvement Project</td>
<td>Vonek Yedala, MD; Jennifer Dotson, DO; Toni Paciolo, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>23</td>
<td>Prazempse Taworski, MD</td>
<td>Late Dosing of Leuprolide and Testosterone Levels &gt;200g/Dl in Prostate Cancer Patients</td>
<td>Stuart Atkinson, MB, ChB; Deborah M. Bolbit-Houle, PhD; Rasul S. Concepcion, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>24</td>
<td>Ali McBride, PharmD, MS, BCOP University of Arizona Cancer Center</td>
<td>Cost Comparison of PARP Inhibitors in Women with Ovarian Cancer (OC) in the US HealthCare Market</td>
<td>Jessica Perharidé, PhD; Craig Gibson, PhD; Gene Weitzel, PharmD, BCOP, CPh</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>25</td>
<td>Hassan Jai, MD</td>
<td>Factors Influencing Survival of Patients Treated for Spinal Metastases at a Regional Cancer Center in Appalachia</td>
<td>Ibra Batool Khan, MD; Ahmad Abu-Haseyph, MD; Vonek Yedala, MD; Hassan Yasin, MD; Todd Gress, MD, MPH; Maria Tronca, MD, FACCP</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>26</td>
<td>Roskasa Zai, PhD</td>
<td>Clinical Pathway and Education Implementation to Support Guideline Adherent Breast Cancer Care for Rural Women Under Age 50</td>
<td>Elizabeth Reed, MD; Robin M. Laby, PhD, MS, RN, AACN, FAAN</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>27</td>
<td>Chashal Guo, PhD</td>
<td>A Digital Solution to Enable Improved Implementation and Usability of NCCN Guidelines®</td>
<td>Matthew Prime, MD, PhD; Vishakha Sharma, PhD; Marc Malimain, BS</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>28</td>
<td>Pamela DeGuzman, PhD</td>
<td>Use of the NCCN Distress Thermometer to Identify and Address Distress During a Telemedicine Visit with Rural Head and Neck Cancer Survivors</td>
<td>Veronica Bernacchi, BSN; C. Allen Cupp, BSW, AND; B. J. Fembowe Shamarai, MHA; Iova D. Hinton, PhD, Mark J. Jamieson, MD, PhD; Debra Lynn Lewandowski, BSN, MBA; Christi Sheffield, MPA</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>29</td>
<td>E. S. Delpassad, MD</td>
<td>First US Prospective Evaluation of Performance of 404C DOTATATE PET/CT in Somatostatin Expressing Neuroendocrine Tumors</td>
<td>Rodolfo Nunez, MD; D. Ranganathan, PhD; N. Wagh, PhD; A. Shafie, MD; A. Gabel, MD; I. Treves, MD, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>30</td>
<td>Ju Wang, MD</td>
<td>Comparative Efficacy, Safety and Acceptability of Single-Agent Poly (ADP-ribose) Polymerase (PARP) Inhibitors in BRCA Mutated HER2-Negative Metastatic or Advanced Breast Cancer: A Network Meta-Analysis</td>
<td>Ye Zhang, MM; Long Yuan, MM; Lin Ren, MM; Yi Zhang, MD; Xiaciei Qi, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>31</td>
<td>Catherine Lockhart, MS, PharmD, PhD Biologic and Biomarkers Collective Intelligence Consortium</td>
<td>Granulocyte Stimulating Colony Factor Use, Characteristics and Treatment Patterns in the United States: An Updated Analysis by the Biologics and Biomarkers Collective Intelligence Consortium</td>
<td>Cara McDermott, MS, PharmD, PhD; James Marshall, MPH; Aaron Mendelson, PhD, MPH; Pamala Pawlowski, PharmD; Jeffrey Brown, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>32</td>
<td>Kimberly Ball, RN, MBA</td>
<td>Feasibility: Building a Patient Centered Program</td>
<td>NA</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>33</td>
<td>Jung Lin, PhD</td>
<td>Treatment Patterns, Healthcare Resource Utilization and Patient-Reported Outcomes for Patients Diagnosed with Small Cell Lung Cancer</td>
<td>Sanjosh Gautam, PhD; Nan Hu, MD; Debra Wertz, PharmD; Goyeeye Adeboyede, MD, MS, MBA; Sumeet Kachroo, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>34</td>
<td>Amy N. Zitochio, DO, MPH, FAAP Avalon Healthcare Solutions</td>
<td>Aligning Genetic Panel Utilization with Clinical Practice Guidelines Through Education</td>
<td>Jeremy L. Day-Stroms, MA; PA; Paige Xu, MPH; Erin Kran, PhD; Tanema Sankova, MSc, PhD, DARBC</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>35</td>
<td>Rudolph Navari, MD, PhD, FACP O’Neal Comprehensive Cancer Center at UAB NCCN Member Institution</td>
<td>Pooled Analysis of Phase 3 Studies Comparing a Single-Dose Fixed Combination of Neuplatip/ Polsonotrocept (NEPA) vs. a 3-day Aprepitant-Based Regimen (APR) for Prevention of Chemotherapy-Induced Neutropenia and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)</td>
<td>Erminio Bonizzi, PhD; Rita Wickham, PhD, MS, BSN; Rebecca Clark-Brown, RN, BSN, OCN</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>36</td>
<td>Grace Cheng, MD</td>
<td>Hyperemesis Disorders of Pregnancy and Subsequent Breast Cancer Risk</td>
<td>Lisa E. Vaughan, MD; Amy L. Weaver, MD; Michelle Mikelie, PhD; Wendy White, MD; Andrea Kattah, MD; Veena Garovic, MD, PhD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>37</td>
<td>Christopher Black, PhD, MPH &amp; Co., Inc.</td>
<td>Determinants of Time to Treatment Initiation in Metastatic Cancers</td>
<td>Welin Meng, MS; Sirinivasan Rajagopalan, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>38</td>
<td>Zikun Wang, MPh</td>
<td>Clinical Pathway-Related Features as a Predictor of Female Triple-Negative Breast Cancer Metastasis and Survival in the United States, 2010-2015: A Logistic Regression Model From NCIC Surveillance, Epidemiology and End Results (SEER) Database</td>
<td>Zheyu Li, MD; Zhongzhe Chen, PhD; Yi Dong, MD, PhD</td>
<td>Epidemiology/Risks/Prevention</td>
</tr>
<tr>
<td>39</td>
<td>Marvin Fancool, DD        Franciscan-Midwestern University</td>
<td>OBCSE: Oncologist Based Emphasis on Survivor Education-Physician Driven Weight Loss Counseling and Outcomes in TNBC</td>
<td>Caitlin Carter, DO; Nicholas Guatashoff, DO; Saherbier Abbasi, DO; Grevani Saggyed, DO, Kathryn Hockenemith, DO; Amy Sten, PhD; Maseoil Ghous, DO; Krishan Sinravan, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>40</td>
<td>Alaina Lee, BSN, RN, OCN Janssen Scientific Affairs, LLC</td>
<td>Impact of Social Determinants of Health on Unplanned Acute Care Service Utilization for Patients with Hematologic Malignancies</td>
<td>Joyce LaMon, NHS, MSS; Besa Smith, MD, PhD; Tyler Smith, MD; Alaina Lee, BSN, RN, OCN; Kai Zu, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>41</td>
<td>Jung-Min Lee, MD</td>
<td>Lymphedema in Patients with Non-Endometrial Endometrial Cancer</td>
<td>NA</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>42</td>
<td>Benigno Emmanuel Rodriguez Soto, MD Centro Medico AMC</td>
<td>Metastatic Renal Cell Carcinoma and Immunotherapy Experience in a Third Level Hospital in Mexico City</td>
<td>Lorena Lopez Zepeda, MD; Daniela Vazquez Juarez, MD; Alejandro Nogues Ramos, MD; Alberto Villalobos Prieto, MD; Samuel Rivera Rivera, MD; Guillermo Manuel Olivares Beltran, MD; Raquel Gerson Cwilich, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>43</td>
<td>Dadasahab Akolkar, PhD</td>
<td>Clinical Utility of Encyclopedic Tumor Analysis to Treat Breast Cancer Patients Who Have Failed Standard of Care Treatments</td>
<td>Darsanna Pali, MD; Ambitious Ramale, MD; Revati Pali, MD; Sachin Aparna, MS; Santab Pali, MS; Pradip Fulmali, MS; Pradip Dharne, PhD; Naval Srivastava, PhD; Ajay Srivastava, PhD; Rajin Datar, BS</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>44</td>
<td>Henry Hinz, PhD</td>
<td>Data from Electronic Prior Authorization Supports Real-World Evidence Generation: Contemporary Changes in the Treatment of a NSCLC</td>
<td>Lindsay R. Sangaranlinh, MPH; Aaron S. Mansfield, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>45</td>
<td>Karen Hock, PT, MS, CLT-LANA The James Cancer Hospital and Solove Research Institute NCCN Member Institution</td>
<td>Prehabilitation Model of Care for the Patient with Breast Cancer</td>
<td>Carl Utendorf, DPT, PT, MBA,CLT-LANA</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>46</td>
<td>En Cheng, MD, MSPh</td>
<td>Geographic Variations of Potentially Curative Treatments for Hepatocellular Carcinoma in the United States: A SEER-Medicare Study</td>
<td>Peiyin Hung, MSPh, PhD; Shi-Yi Wang, MD, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>Poster #</td>
<td>Presenter and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------</td>
<td>-------</td>
<td>------------</td>
<td>----------</td>
</tr>
</tbody>
</table>
| 47      | Christopher D’Avella, MD  
NCCN Member Institution | The Direct Refererral Unit: Clinical Outcomes and Experience with a Specialized Urgent Care Center for Oncology Patients | Peter Wholey, DO, MBA; Emily Milani, BS; Brian Egleston, MPP, PhD; Martin Edelman, MD; James Holdstrom, MD, MBA; Kenneth Patrick, MD; Jessica Bauman, MD | Outcomes and Health Services Research |
| 48      | Vanessa Petry Helena Bruque, MD  
Universidade de Sao Paulo | Radiotherapy-Induced Malignancies in Breast Cancer Patients with Pathogenic Germline Variants TP53 in an R337H-Mutation Enriched Cohort | Renata Colombo Bonaldo, MD; Luiz Antonio Sena, MD; Daniela Benvenutu Hannemann Cohn, MD; Alyne Cagnacci, MD; Roberta Campos, MD; Maria Del Pilar de Esteva Diz, MD; PhD; Maria Candida Barroso Villares Frazoso, MD, PhD | Clinical Oncology |
| 49      | Prianka Singh  
Bristol-Myers Squibb | A Systematic Literature Review of First-Line (1L) Treatments for Patients with MGMT (O-6-METHYL-GUANINE-DNA METHYLTRANSFERASE) Methylated and Unmethylated Glioblastoma Multiforme (GBM) | Rosalin Postema, PharmD; Shevta Yakub, MS; Anagha Gogate, MS; Alex Z, Fu, PhD; Gautamjeet Mangat, MS | Outcomes and Health Services Research |
| 50      | Nusrat Jahan, MD  
Texas Tech University Health Sciences Center School of Medicine | Relative Risk of Various Endometropathies Associated with the Use of Immune Checkpoint Inhibitors in the First-Line Treatment of Advanced Renal Cell Carcinoma: A Systematic Review and Meta-Analysis | Francis Mogollon-Ortiz, MD, Miguel Guevarra, MD; Somadeb Bar, MD; Fred Hambelton, MD; Lukman Tijani, MD; Shabnam Rehman, MD | Best Practices in Implementation and Use of Clinical Practice Guidelines |
| 51      | Sumanesh Kashmar, PhD  
Mars & Co., Inc. | Association of Patient-Clinico-Genomic Characteristics with Tumor Mutational Burden in Small Cell Lung Cancer: An Observational Study | Changzhi Shen, PhD; Kausal Dasal, PhD; Jinghua He, PhD; Fan Jin, MD; Shuvayu Sen, PhD | Outcomes and Health Services Research |
| 52      | Brian Seal, PhD, MBA, PPh  
AstraZeneca Pharmaceuticals, LP | Quantifying Patient Preferences for Attributes Associated with First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer | Candice Yong, PhD; M. Janelle Camborn-Mollott, PhD; Oliver Will, MD; Martine C. Macalalad, PhD; Kelly Clay, PhD; Emily Mulvihill, MBA; Ion Cotaria, MD, PhD; Ranee Mehra, MD | Outcomes and Health Services Research |
| 53      | Candice Yong, PhD  
AstraZeneca Pharmaceuticals, LP | Quantifying Caregiver Preferences for Attributes Associated with First-Line Treatment of Metastatic Non-Small-Cell Lung Cancer | Brian Seal, PhD, MBA, PPh; M. Janelle Camborn-Mollott, PhD; Oliver Will, MD; Martine C. Macalalad, PhD; Kelly Clay, PhD; Emily Mulvihill, MBA; Ion Cotaria, MD, PhD; Ranee Mehra, MD | Outcomes and Health Services Research |
| 54      | Amy Allen, MA, MS  
West Virginia University Cancer Institute | Bridge to Good Living: Outcomes and Financial Implications of a Lung Cancer Survivorship Program in West Virginia | Adrienne Dockworth, MSN, APN, FNP-C; Samaneh Khatra, PharmD; Stephanie Kennedy-Rea, EdD | Outcomes and Health Services Research |
| 55      | Nandan Shanbhag, MD  
Mount Saint John's Medical Centre | Breast Cancer at Mount Saint John's Medical Centre - Mapped | Joycelyn Condace Phillips, NP | Epidemiology/Risks/Prevention |
| 56      | Allyson Karnska, BA  
Pharmaceutical International | Current Utilization of Genomic Testing and Barriers to Optimal Patient Care: A Targeted Literature Review | Yrilt Aguirre, MPH; Glycysa Adelakoya, MD, MS, MBA | Outcomes and Health Services Research |
| 57      | Adrian Legarai, MD  
Palminto General Hospital | Laparoscopic Microwave Ablation for the Treatment of Primary and Metastatic Liver Malignancies | Vanitha Vasudevan, MD; Amit Saxty, MD; Jeronimo Geraldoz de Llano, MD | Clinical Oncology |
| 58      | Michelle Mokul | Quality Outcomes in Colorectal Cancer | Neeshka S. Makani, MD | Outcomes and Health Services Research |
| 59      | Heather Wright, MD  
Memorial Healthcare System | Time is On Our Side: Concomitant Needle Biopsy and Wire-Free Localization of Axillary Lymph Nodes May Decrease Redundant Preoperative Needle Localization in BI-RADS 5 Breast Cancer Patients | Mayra Frau, MD; Erica Bloomquist, MD; Mary Hayes, MD | Clinical Oncology |
| 60      | Cinthia Moriska, MD, PhD  
University of Sao Paulo Hospital Sirio Libanes Advantage Health | Can Antisense Oligonucleotides Targeted to K-ras Gene Inhibit the Tumor Growth, Invasiveness and Expression of MMP-2 and MMP-9 in In Vivo and In-Vivo in Hamster Experimental Pancreatic Carcinoma Model? | Marcel Cesarane Cesar Machado, MD, PhD; Jose Pinhata Otchis, MD, PhD; Luma Princes Schneider, MD; Edgard Mexiquita Rodrigues Lima, MD; Marcelo Engracia Garcia, MD, PhD; Seiji Saito, MD, PhD; Akiharu Watanabe, MD, PhD; Eduardo Kenichi Moriska, BSc; Ding Cheng Huang, Sc | Pre-Clinical Oncology |
| 61      | Eric Lander, MD  
Vanderbilt University Medical Center  
NCCN Member Institution | The HER2 FISH Ratio is a Predictor of Pathologic Complete Response Among Patients with HER2+ Breast Cancer Receiving Neoadjuvant Anti-HER2 Doublet Therapy Without Chemotherapy | Rusy Hu, MD, MPH; Katherine Rappazzo, MD; Hsi-lan Chen, PhD; Vandana Abrahamson, MD | Clinical Oncology |
| 62      | Naveen Ramanujam, MD  
Navya | Comparison of Treatment Plans Feasible Through AI-Enabled Multidisciplinary Online Tumor Board Solution vs. NCCN Based Clinical Decision Support System (CDSS) | C. S. Pramesh, MD; Githa Brivadas, MD; Vikas Ostwal, MD; Anant Ramaswamy, MD; Ajo Mathew, MD; Mahesh Gid, MD; Supriya Chopra, MD; B. J. Suri, MD; Durgasree Pandey, MD; Rajendra A. Badwe, MDS; Bhavna Sirohi, MD | Bioinformatics/Information Technology Sciences |

Enter to Win! ENTRY FORMS ARE INCLUDED IN THE CONFERENCE BAG.

NCCN General Poster Sessions Raffle

More than 100 posters will be presented in the NCCN Exhibition Hall on Friday, March 20 and Saturday, March 21. Drop off your completed Poster Session Form(s) at NCCN Booth #120 and enter to win a Fitbit Charge 3!

Drawings will take place on Friday, March 20 at 3:55 PM and Saturday, March 21 at 3:45 PM. Winners do not need to be present at time of drawing.

Drawing times are approximate.
<table>
<thead>
<tr>
<th>Poster #</th>
<th>Presenter and Institution</th>
<th>Title</th>
<th>Co-Authors</th>
<th>Category</th>
</tr>
</thead>
<tbody>
<tr>
<td>63</td>
<td>Rebecca Arndt, MD</td>
<td>Targeting TGF-β in Ovarian Cancer Results in Decreased Tumor Burden and Improved T cell Immune Response</td>
<td>Brandon M. Roane, MD; Selene Mesa-Perez, PhD; Whitney N. Goldberg, MD; Astrid Klimscha, MS; Michael J. Bono, MD; Lisa A. Simon, PhD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>64</td>
<td>You Cao, MPhil, ScD</td>
<td>Racial Differences in Clinical Pathophysiologic Features and Survival of Early- and Average-Onset Colorectal Cancer</td>
<td>Hangy Chen, MD; Jie Liu, MD; Xingwu Zong, MPH; Ai Zhang, MPH; Jennifer Tappenden, MFA; Thomas Wain, BS; Deyak Chatterjee, M; Ryan Courtney Fields, MD; Graham Andrew Colditz, MD, PhD</td>
<td>Epidemiology/Risk/Prevention</td>
</tr>
<tr>
<td>65</td>
<td>Edwin Ramos Manuel, PhD</td>
<td>Altering the Local Immune Landscape in Lung Cancer to Improve Checkpoint Inhibitor Therapy</td>
<td>Edith Zuniga, BS; Edwin Ramos Manuel, PhD</td>
<td>Pre-Clinical Oncology</td>
</tr>
<tr>
<td>66</td>
<td>Elizabeth Stewart, MD</td>
<td>Preclinical Pediatric MATCH</td>
<td>Kelly Blankenship, BS; Lauren Hoffmann, BS; Burgess Freeman, PhD</td>
<td>Pre-Clinical Oncology</td>
</tr>
<tr>
<td>67</td>
<td>Cecilia Young, MD</td>
<td>Rapid Point of Care Assay by Ionothermal PCR for Acute Promyelocytic Leukemia Diagnosis</td>
<td>Bret Helton, BS; Jerald Radich, MD</td>
<td>Bioinformatics/Information Technology Sciences</td>
</tr>
<tr>
<td>68</td>
<td>Tim Luetkens, MD</td>
<td>CD229 CAR-T Cells Eliminate Multiple Malignant and Tumor Propagating Cells but Show Limited Targeting of Normal T Cells</td>
<td>Sabamath Venkaj Reddiah, MD; Sandra D. Scherer, PhD; Patricia Davis, PhD; Erica R. Vander Mause, PhD; Michael L. Olson, PhD; Sara Yousef, PhD; Jens Paree, MD; Yasmina Al-Abedi, PhD; K David Li, MD; Rodney R. Miles, MD; William Matsui, MD; Alan L. Weil, PhD; Djordje Almaschi, MD</td>
<td>Pre-Clinical Oncology</td>
</tr>
<tr>
<td>69</td>
<td>Andrew B. Banksy, MD</td>
<td>Sex-Based Disparities in Receipt of Care and Survival in Malignant Pleural Mesothelioma</td>
<td>Christopher A. Ahern, PhD; Srinivasa Venkata, PhD; Vivek Verma, MD; Emily J. Anselt, MD, PhD; Christopher M. Wright, MD; Ethan P. LudmNM, PhD; Christopher G. Berlind, PhD; William D. Lindsay, MD; Sumith Grover, MD; MPH; Keith A. Cengel, MD, PhD; Charles B. Simon, II, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>70</td>
<td>Cindy Tran, MPhil, PhD</td>
<td>Integration of Tobacco Treatment into Cancer Care at Stanford Health Care</td>
<td>Brittany PIs, MS, BS, RN; Matthew Kendra, PhD; Rachelle Mirik, MPH; Judith J. Prochaska, PhD, MPH</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>71</td>
<td>Aje John, BSN, MPhil, PhD</td>
<td>The Impact of Adherence to NCCN Biomarker Testing Guidelines on Survival for Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer</td>
<td>Saiyu Yang, PhD; Jaya Madala, MS; Roma Shah, MPH</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>72</td>
<td>Judy George, PhD</td>
<td>Real-World Study of Factors Associated with Breast Conserving Surgery for Females Diagnosed with Early Stage Breast Cancer</td>
<td>Joseph Thacu, MS; M. Christopher Roebuck, PhD, MBA; Fredy Reyes, PhD; Eul E. Ariagga, MS; Gretchen F. Jackson, MD, PhD; Irene Dankova-Mulan, MD, MPH</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>73</td>
<td>Jifang Zhou, MD, MPhil</td>
<td>University of Washington College of Pharmacy</td>
<td>Diabetes Complications and Risks of Breast Cancer Recurrence Among Older Women</td>
<td>Alexmaged A. Ahdab, MD; Nadia A. Nabulsi, MPH; Nita A. Mikhael, BS; Inyong Lee, MD; Noomi Y. Kn, MD, MPH; AM; Denise B. Simeone, PhD, MPH; RPH; Gregory S. Calip, PharmD, MPH, PhD</td>
</tr>
<tr>
<td>74</td>
<td>Saurabh Pararangma, MD</td>
<td>University of Kentucky Medical Center</td>
<td>Optimal Timing of Radical Surgery from Diagnosis in Muscle Invasive Bladder Cancer (MIBC)</td>
<td>Guan Chen, PhD; Bin Huang, MD, PhD; Peng Wang, MD, PhD; Zhiyin Sun, MD</td>
</tr>
<tr>
<td>75</td>
<td>Sonali Agrawal, BS</td>
<td>Fox Chase Cancer Center</td>
<td>Provider Versus Patient Reported Outcomes (PROs) in Colorectal Cancer (CRC) Patients (Pt) Undergoing Systematic Therapy (Sync): A Real World Experience</td>
<td>Caitlin R. Messer, MD; Sundeep Agravat, MD; Elizabate Andorch, MD; Sunil Adiga, MD; Erat Dostan, MD; Crystal S. Denninger, MD; William H. Ward, MD; Jeffrey M. Farma, MD; Namrata Vijayapragada, MD</td>
</tr>
<tr>
<td>76</td>
<td>Anthony D. Yang, MD, MS</td>
<td>Northwestern University Feinberg School of Medicine</td>
<td>Are You Ready? Assessing Readiness to Implement Quality Improvement in Hospitals Participating in a Breast Cancer Collaborative</td>
<td>Ashley Byers, MBA; Eileen Njoo, MPH; Julie K. Johnson, MSPh, PhD; Karl Y. Bilimoria, MD, PhD; Lindsey Kreutzer, MPH</td>
</tr>
<tr>
<td>77</td>
<td>Joong Lim, PhD</td>
<td>Concience Health AI</td>
<td>Progression-Free Survival, Overall Survival, and Tumor Response for Patients Diagnosed with Small Cell Lung Cancer who Received First-Line Systemic Therapy</td>
<td>Sambamuthy Gobu, PhD; Hai Hu, MS; Debra Worts, PharmD; Gabyoga Abolinska, MS, MD, MBA; Sumeeth Kasurth, PhD</td>
</tr>
<tr>
<td>78</td>
<td>Alexandra Hunt, MS</td>
<td>Fox Chase Cancer Center Member Institution</td>
<td>Prevalence and Correlates of Psychological Distress in Patients Enrolling on Phase I Clinical Trials Using the NCCN Distress Thermometer and Problem List</td>
<td>Elizabeth Handorf, PhD; Hyun Kwon, MD; Matthew Blau; Tara Chertock, MA; Carolyn Fang, PhD; Michael J. Hall, MD, MS; Rohan Jain, MD, MS</td>
</tr>
<tr>
<td>79</td>
<td>Dwight Owen, MD, MS</td>
<td>Ohio State University NCCN Member Institution</td>
<td>A Phase 2 Trial of Nivolumab and Vemurafenib in Advanced Melanoma to Treat Patients (Pts) with a Progression-Free Survival of 6 Months</td>
<td>Lai Wei, PhD; Ananta Gopal, PC; In Zhu, APHN-BC; Sheryl-Ellie Sutfen, CCR; Rafael Jacob, MACPF; Carley Pitcher, CCR; Gregory A. Deller, MD; Claire F. Venscseku, MD; Manisha K. Shah, MS; Bhavana Kondi, MS</td>
</tr>
<tr>
<td>80</td>
<td>Benson Emmanuel Rodriguez Soto, MD</td>
<td>Centro Medico ABC</td>
<td>Use of Cyclin Dependent Kinase 4/6 Inhibitors in Homone Receptor Positive HER2 Negative Metastatic Breast Cancer in a Third Level Hospital in Mexico City</td>
<td>Lorena Lopez Zepeda, MD; Alejandro Noguez Ramos, MD; Daniela Vazquez Aguilar, MD; Daniela Sheid Gerson, MD; Yasmin Carolina Blanco Vazquez, MD; Samuel Rivera Rivera, Alberto Villalobos Pinto, MD; Gabriela Oliva Regaldo Poma, MD; Ivan Solceda Sull, MD; Fernando Perez Zicner, MD; Christian Patricia Camacho Limas, MD; Juan Alberto Serrano Olve- na, MD; Alvaro Agapay Gonzalez, MD; Guillermo Manuel Olivarres Beltran, MD; Raquel Gerson Cechit, MD</td>
</tr>
<tr>
<td>Poster #</td>
<td>Presenter and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>----------</td>
<td>--------------------------</td>
<td>-------</td>
<td>------------</td>
<td>----------</td>
</tr>
<tr>
<td>91</td>
<td>Sharon Steingass, RN, MSN, AOCN</td>
<td>Lifeline for Oncology Patients - Telephone Triage</td>
<td>NA</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>92</td>
<td>Kaushal Desai, PhD</td>
<td>Real-World Utilization and Coding Variability in Medical Claims for Next-Generation Sequencing (NGS)-Based Diagnostic Tests among Cancer Patients in the US</td>
<td>Gillian Hooker, PhD, SiM, LGCC; Shreyoga Adeleye, MD, MS, MBA; Sumesh Kachroo, PhD; Shuyuan Banerjee, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>93</td>
<td>Xiaojie Yang, PhD</td>
<td>Characteristics, Treatment Patterns, Healthcare Resource Use and Costs among Pediatric Patients Diagnosed with Neurofibromatosis Type 1 and Plexiform Neurofibromas: A Retrospective Database Analysis</td>
<td>Kaushal Desai, PhD; Neha Agrawal, MA; Kirti Mirchandani, MSc; Sugrap Chatterjee, MA; Eric Sarpong, MD; Shuoyue Shen, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>94</td>
<td>Ashley Tahab, MS, MPH</td>
<td>Caligene Corporation</td>
<td>David Hugger, PharmD; Ronda Copher, PhD; Marc Tan, PhD; Al McBride, MS; PharmD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>95</td>
<td>Anna Hung, PharmD, PhD, MS</td>
<td>Duke Cancer Institute NCCN Member Institution</td>
<td>Concurrent Chemoradiation Treatment Patterns for Stage III Non-small Cell Lung Cancer in Veterans</td>
<td>Kyung Min Lee, PhD; Yehong Li, MD; Julie A. Lynch, PhD; RN; Pradeep Poonnen, MD; Bradley J. Heine, PhD; Olga K. Efimova, MD, PhD; Candice Yong, PhD; Brian Seal, PhD, MBA; Trudy Pendergrast, MPH; Michael Kelley, MD; Shelby D. Reid, PhD</td>
</tr>
<tr>
<td>96</td>
<td>Nishanthi Thalambedu, MD</td>
<td>Abington Jefferson Health</td>
<td>A Meta-Analysis on the Safety of Pansorbin Compared to Elizumab and Isocomb for the Treatment of Multiple Myeloma</td>
<td>Waqas Ullah, MD; Ammar Ashqaq, MD; Yasar Khan, MD; Mishal Shaukat, MD; Gihan Zhang, MD</td>
</tr>
<tr>
<td>97</td>
<td>Mustafa Cetiner, MD</td>
<td>Avicenna Medical Hospital</td>
<td>Cancer Perception, Myths and Disparities Among Turkish Population: A Qualitative Study</td>
<td>Aydin Yetlik, MD</td>
</tr>
<tr>
<td>98</td>
<td>Murali Sundaram, MSA, PhD, Janssen Scientific Affairs, LLC</td>
<td>Health-related Quality of Life and Treatment Satisfaction in Chronic Lymphocytic Leukemia (CLL) Patients on Brutinib Compared to a Reference Group on Other CLL Treatments in a Real-World US Cross-Sectional Study</td>
<td>Kathleen L. Devine, PharmD; Dolly Sharma, PhD; Qing Hanhaw, MD, PhD; Jeromeh Turkaew, PhD; Jacqueline C. Barrington, MD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>99</td>
<td>Smitha Sivaraman, MD</td>
<td>Incyte Corporation</td>
<td>Treatment Patterns and Time Trends for Intrahospital Cholangiocarcinomas (CCA) Patients: A Real-World Retrospective Claims Study</td>
<td>Lincy Lal, MD, PharmD; Scott Bunnin, MPH; Dilan Pareaganous, PhD; Anna Tschemak, PhD; Susan Smogdass, MD; Shreekant Parawaram, PhD</td>
</tr>
<tr>
<td>100</td>
<td>Gianfranco Puppo, MD</td>
<td>Ospedale di Macerata</td>
<td>Real-Life Experience of Treatment with Anti-Programmed Cell Death-1 (PD-1) or Programmed Death-Ligand 1 (PD-L1) Antibodies in Patients with Non-Small Cell Lung Cancer (NSCLC)</td>
<td>NA</td>
</tr>
<tr>
<td>101</td>
<td>Frank Xiaoqing Liu, PhD</td>
<td>EMD Serono, Inc.</td>
<td>Budget Impact Analysis of Avatulum Plus Aslibin for the First-line Treatment of Patients with Advanced Renal Cell Carcinoma</td>
<td>Kirstin Heinrich, MPH; Catriona News, BS; Bing Zheng, MD; Adam Kaule, BS</td>
</tr>
<tr>
<td>102</td>
<td>Audrey Deemere, PharmD</td>
<td>Adaptive Biotechnologies</td>
<td>Real-world Minimal Residual Disease (MRD) Assessment and Trends Using clonoSEQ in B-Cell Acute Lymphoblastic Leukemia and Multiple Myeloma</td>
<td>Anthony Hewitt, MB; Ben Eckert, MS; Lih Wei Lee, PhD</td>
</tr>
<tr>
<td>103</td>
<td>Adrian Legaspi, MD</td>
<td>Palmetto General Hospital</td>
<td>Initial Experience of Robotic Assisted Colorectal Surgery in a Community Hospital</td>
<td>Vanita Vadevan, MD; Amit Sastry, MD; Jeronimo Garcia-de Llano, MD; Maricel Puja-Conl, MD</td>
</tr>
<tr>
<td>104</td>
<td>Kimberly Rose Hedinstrom, PharmD</td>
<td>eviCore Healthcare</td>
<td>Prescriber-Assigned Febrile Neutropenia and Emetic Risks Compared to the NCCN Risk Classification for Cancer Treatment Regimens</td>
<td>Margaret Rausa, PharmD; Eric Grabias, MD, FAAP; Stephen Hamilton, MD</td>
</tr>
<tr>
<td>105</td>
<td>Amanda Cook, BA</td>
<td>InfuFACT, Inc.</td>
<td>Pilot Testing of InfuFACT™, an Online Tool to Facilitate NCCN GuideLine®-Compliant Referrals for Cancer Genetic Counseling and Increase Access to Care</td>
<td>David F. Kanes, MD; Lynn McCann, MSBA; Lee F. Schroeder, MD, PhD; Kari Million, MS; Sofia Monopoli, PhD; Diane Harvey, MD; Philip Zavaore, MD; Janice Famire, MD; Susan Ernst, MD; Jasmine Parvaz, MD</td>
</tr>
<tr>
<td>106</td>
<td>Courtney Ramus, MPH</td>
<td>Avanos Health</td>
<td>A Tool Preparing Patients with Stage III Non-Small Cell Lung Cancer for Shared Decision-Making: Validating Acceptability and Usability</td>
<td>Candice Yong, PhD; Dominica Mai, MD; Camille Bolser, BA; Tina Bard, BA; Joshua Sedman, PhD; Alexia Clary, PhD, MSW; Bjorn Bolinder, MBA</td>
</tr>
<tr>
<td>107</td>
<td>Bianca Leeds, BA</td>
<td>Fox Chase Cancer Center NCCN Member Institution</td>
<td>Psychosocial Support in Older Patients with Metastatic Breast Cancer (MBC) Treated at Community Centers</td>
<td>Callie R. Maksin, MPH; Elizabeth Handorf, PhD; Kelly Flincer, MSN, RN, OCN, CCRC; Rino Seedor, MD; Jennifer S. Wro, MS, MD; Lorri J. Goldstein, MD; Ebral Dolez, MD</td>
</tr>
<tr>
<td>108</td>
<td>Wencai Li, PharmD</td>
<td>Moffitt Cancer Center NCCN Member Institution</td>
<td>Safety and Financial Outcomes of Outpatient Dose-Adjusted EPOCH for B-cell Lymphoma at a Tertiary Comprehensive Cancer Center</td>
<td>Katherine Simonsensd, PharmD, MBA; Katherine Tobon, PharmD; Kevin McCarney, MBA; Timothy Kubal, MD; MBA</td>
</tr>
<tr>
<td>109</td>
<td>Dalia F. Makower, MD</td>
<td>Northeastern University Feinberg School of Medicine NCCN Member Institution</td>
<td>Innovating Patient-Facing Care Pathways in Breast Cancer Using the 4R Model: 4R = Right Information/ Care/ Patient/ Time</td>
<td>Christine Brezina, MD; Julia R. Traxman, PhD, MBA; Kent Hoskins, MD, BA; Cathleen Schaffer, RN, BSN, OCN, CNBC; Bruce D. Raphin, PhD; Melissa A. Simon, MD MPH; Al B. Benson, MD FACCP FASCC; William J. Grabowski, MD</td>
</tr>
<tr>
<td>110</td>
<td>Yedex Pandey, MD</td>
<td>University of Arkansas for Medical Sciences</td>
<td>Fertility Preservation Discussion in Young Adults with Cancer: How Often Are We Documenting?</td>
<td>Arva Roy; Mamajina Konda, MD; Jacob Leffert; Issam Makdour, MD; Appolonia Sasupa, MBA</td>
</tr>
<tr>
<td>111</td>
<td>Lance Brannman, PhD</td>
<td>Massachusetts General Hospital Cancer Center NCCN Member Institution</td>
<td>Real-world Chemoradiotherapy Use Among Unresectable Stage III Non-Small Cell Lung Cancer Patients: A Retrospective Observational Study</td>
<td>Meghan J. Moradian, MD; Kenneth Shermock, PhD; David Merino, PharmD, SM; Brian Seal, PhD; Candice Yong, PhD</td>
</tr>
<tr>
<td>112</td>
<td>Ericson Stoen, MD</td>
<td>University of Colorado School of Medicine NCCN Member Institution</td>
<td>Factors Associated with the Uptake of Adjunct Perioperative in Patients with Stage I-II HER2-Positive Breast Cancer: The University of Colorado in the US Center Experience</td>
<td>Jodi Kaghara, MD; Peter Karbus, MD; Christine Fisher, MD; Jennifer R. Diamond, MD</td>
</tr>
<tr>
<td>113</td>
<td>Matthew Rends, MDUS</td>
<td>Army Brooke Army Medical Center</td>
<td>The Effects of Chemotherapy on the Efficacy of Pneumococcal Vaccination Using Pneumococcal Vaccine Antibody Titers as Corollary</td>
<td>Robert Signignon, MD; Wilfred Dela Cruz, MD, PhD</td>
</tr>
<tr>
<td>114</td>
<td>Pooni Mowry, MSN, RN, OCN, NEA-BC</td>
<td>The James Cancer Hospital and Solvita Research Institute NCCN Member Institution</td>
<td>An Immediate Care Center for Oncology Patients &quot;Symptom Management Doesn’t Require the Emergency Department&quot;</td>
<td>NA</td>
</tr>
<tr>
<td>Poster #</td>
<td>Presenter and Institution</td>
<td>Title</td>
<td>Co-Authors</td>
<td>Category</td>
</tr>
<tr>
<td>---------</td>
<td>--------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>105</td>
<td>Miguel Quirch, MD</td>
<td>A Systematic Review and Meta-Analysis on Micronutrient Toxicities Associated with Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma</td>
<td>Naharal Jahan, MD; Francis Mogollon-Dufo, MD; Lukman Tijani, MD; Shabnam Rehman, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>106</td>
<td>Robert J. Spencer, MS, MBA</td>
<td>Targeted Drug Delivery (TDD) for Cancer-Related Pain Emerging Evidence</td>
<td>Shana E. Brugen, MD; BCN; Kristin Hammond, BS; Lisa M. Stearns, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>107</td>
<td>Nishanth Thalambedu, MD</td>
<td>Comparative Efficacy of Eliotuzumab with Pembrolizumab and Iazomizum in Multiple Myeloma: A Meta-Analysis</td>
<td>Wafa Allah, MD; Yasar Khan, MD; Ammar Ashraf, MD; Gian Zhang, MD; Mdish Shukait, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>108</td>
<td>Kashi Brooks, MS</td>
<td>A Founder CHEK2 Pathogenic Variant in Association with Kidney Cancer</td>
<td>Catherine Steding, PhD; Melissa Holman, MS, LCSG; Rony Girma, PhD; Megan Tucker, MS, LCSG</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>109</td>
<td>Marcia Doniger and Elizabeth Franklin, MSW</td>
<td>Results from a Pilot Study Examining the Impact of Distress Screening and Referral on Cancer Patient Cost and Health Care Utilization</td>
<td>Melissay Allen, BS; Diane Robinson, PhD; Nicole Nicklas, MPH; Alexandra Zaleta, PhD; Melissa Miller, MSW</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>110</td>
<td>Miguel Quirch, MD</td>
<td>A Meta-Analysis on Gastrointestinal (GI) and Hepatic Toxicities Associated with Upfront Use of Immune Checkpoint Inhibitor and Anti-Angiogenic Tyrosine Kinase Inhibitor Combinations for Advanced Renal Cell Carcinoma</td>
<td>Naharal Jahan, MD; Meda Srikula, MD; Fred Hardwick, MD; Lukman Tijani, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>111</td>
<td>Jordan McDonald, BS</td>
<td>Effect of Tumor Grade on Neoadjuvant Treatment Outcome in Esophageal Cancer</td>
<td>Rutka Mehta, MD; Sarah Hofte, MD; Jose Pimentel, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>112</td>
<td>Neha Verma, MD</td>
<td>A Case Series of Ecypthic CushionSydrome in Apical Lung Carcinoma</td>
<td>Manisha Shah, MD; Luma Ghali, MD; Lawrence Kirshner, MD; Mayumi Endo, MD; Bhavna Konda, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>113</td>
<td>Chia-Wen Lin, PhD</td>
<td>Real-World Adherence and Persistence of ALK Inhibitors in patients with Non-Small Cell Lung Cancer (NSCLC)</td>
<td>Smita Ogale, PhD; Eruo Yang, MS; William Wong, PharmD; Ayar Khan Qam, MD, PhD</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>114</td>
<td>Maria Mordir, HSSc</td>
<td>Lymphnode Eliminating the Burden of Lymphoma in Cancer Patients Requiring Nodal Dissections: A Pilot Study</td>
<td>Laura Bave, MD; Audrey Libak, MD; Muslim Montazui, MD, MSc, FRSCS; Carolyn Nixom, MD, MSc, FRSCS, FACS</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>115</td>
<td>Abigail Chan, MD</td>
<td>Uses of Supportive and Palliative Care Indicators Tool in Cancer Patients: A Validity Study</td>
<td>Jin Le, DD; Amy Yu, ML; Aimi Roul, MD; Chris D’Adamo, PhD; Patrick Judson, MD; Kenneth Miller, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>116</td>
<td>Jasmin Eugene, PharmD</td>
<td>Retrospective Evaluation of VESP Inhibitor-Associated Hypersensitivity at a Community Cancer Center</td>
<td>Carli Nestehate, PharmD, BCOP; Scott Overmier, PharmD, BCPS</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>117</td>
<td>Jung-Jie Kang, MD, PhD</td>
<td>Prognostic Factors in Major Salivary Gland Tumors Treated with Adjunctive Radiation Therapy</td>
<td>Hannam Verma; Kavitha Zakeri, MD; Huali Wang, MD; Dan Fan, MD; Ming Fan, MD; Anna Lee, MD MPH; Satin Kilgari, MD; Linda Chen, MD; Yv Yu, MD; C. Jillian Tae, MD PhD; Sean McBride, MD; MPH; Husamem Riaz, MD; Daphna Galikoon, MD; Shlomi Ho, MD PhD; Eric Sherman, MD; Lara Dunn, MD; Joy D. Boyle, MD; Richard J. Wong, MD; Ian Gandy, MD PhD; Nancy Y. Lee, MD</td>
<td>Clinical Oncology</td>
</tr>
<tr>
<td>118</td>
<td>Steven Schwatz, MD</td>
<td>International Adaptation of the Resource-Stratified NCCN Frameworks for Breast, Cervical and Rectal Cancers in Bolivia</td>
<td>Claua B. Solis, BS; Marisol Marmol, Marco A. Vasquez, MD; Robert W. Carlson, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>119</td>
<td>Cole Friedes, BS</td>
<td>Comparative Outcomes of Patients with Loco Regional Recurrent Disease Versus De Novo Locally Advanced NSCLC Treated with Definitive Therapy</td>
<td>Nick Ma, MD; Wei Fu, SICh; Pujin Han, MBBS, MHS; Ranh Voong, MD, MPH; Russell Hales, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>120</td>
<td>Gabriela Villanueva, MD</td>
<td>Using Promotoras in a US-Mexico Hispanic Border Community to Provide Palliative Care</td>
<td>NA</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>121</td>
<td>Courtney Kramer, BS</td>
<td>&quot;Write to Recover&quot;: The Impact of Group Led Creative Writing on Physical Health Outcomes in Cancer Patients</td>
<td>Darya S. Nesteva, BS; Junjie Zhu, PhD; Moniala Kojok, MD; Julone Collino, PA-C; Cristina Truca, MD; Aditya Joshi, MD; Michael Hayes, MD; Erika F.H. Saunders, MD; Joseph J. Drabick, MD; Monika Joshi, MD, MRCP</td>
<td>Outcomes and Health Services Research</td>
</tr>
<tr>
<td>122</td>
<td>Cinzia Morlko, PhD</td>
<td>Can Green Tea Extract Inhibit the Tumor Growth and Invasiveness of 5-FU and Gemcitabine-Resistant Paclitaxel and Methotrexate Cell Lines in a Hamster Pancreatic Cancer Model?</td>
<td>Marcel Cernpeua Cesar Machado, MD; PhD; Josey Pintaha Otoch, MD; PhD; Luca Princess Schneider, MD; Edalih Meza Rodrigues Lima, MD; Marcelo Encarzcia Garcia, MD; PhD; Josued Silva, MD; PhD; Alessandro Costa, MD; Victor Herrera; Paolino Aguir; Elenor Herrera; Saltia Aguir; Maycon Kubik; Amelia Silva; Kennedy Silva; Eduardo Morikita, BS; Cheng Ching Huang, BS</td>
<td>Pro-Clinical Oncology</td>
</tr>
<tr>
<td>123</td>
<td>Ahmad Abu-Hashney, MBBS</td>
<td>The Efficacy of Cost-Effective Fixed Dose of Rasburicase Compared to Weight-Based Dose in Treatment and Prevention of Tumor Lysis Syndrome (TLS)</td>
<td>Mena Shenouda, MD; Mohamed Al-Sharadi, MD</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>124</td>
<td>Kristen Burns, BSN</td>
<td>Oncology Nursing Existence Practice and Research Committee: Enhancing Continuity and Improving Patient Outcomes Across Oncology Service Lines</td>
<td>Archana Shenoy, DNP; Nicole Turcogu, MSN</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>125</td>
<td>Mohamed Mahvuor, MSc</td>
<td>Comparative Study Between the Clinical Effect of Palonosetron and Granisetron as Antiemetic Therapy for Patients Receiving Highly Emetogenic Chemotherapy Regimens</td>
<td>Gamal Abd el khalek Es- Azab, PhD; Hisham Ahmed Tawfiq, PhD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>126</td>
<td>Mohammad Khan, DO, MSBS</td>
<td>A Team-Based Model to Promoting Hospice Utilization in High Risk Oncology Patients Through Individual Care Plan Development</td>
<td>Benjamin Switzier, DO, MHSA, MD; Sarah Lee, PhD; Joseph Hosley, MBB, CPPS; Christa Poole, LiBiW-B, OBW-C; Giris Chandra Kunaparody, MD; Ruth Lagan, MD; Berta Montes, MD, MB</td>
<td>Quality Improvement</td>
</tr>
<tr>
<td>127</td>
<td>Karina Mayra Alaga, MD</td>
<td>Evaluation of Glioblastoma Adverse Events in Colorectal Cancer Management in a Private Clinic in Lima, Peru</td>
<td>Fradic Gil-Oliveira, MD; Laura Perez, MD; Gisely Hijar, MD; Edward Lopez, MD; Cindy Alcarras, MD; Mariar Serrano, MD; Claudito Flores, Lic; Alonso Diaz, MD; Jose Gutierrez, MD; Alfredo Aguilar, MD</td>
<td>Best Practices in Implementation and Use of Clinical Practice Guidelines</td>
</tr>
<tr>
<td>128</td>
<td>Mohamed Ali Maer, MS</td>
<td>National Cancer Institute Egypt National Cancer Institute Experience with Genetic Anastrozole (Anastrozol, Hikma) in Newly Diagnosed Postmenopausal Female Egyptian Patients with Low Burden/Visceral Metastatic Breast Cancer</td>
<td>Abdulhamid Mohamed Fouad, MD; Mariam Magd Eldosaid, MD</td>
<td>Clinical Oncology</td>
</tr>
</tbody>
</table>
Visit the Merck Booth and Learn More About KEYTRUDA

• Approved indications
• Resources for health care professionals
• The Merck Access Program
• KEY+YOU Patient Support Program